{"gene":"PRL","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1981,"finding":"Human prolactin (PRL) cDNA was cloned and sequenced, revealing the complete coding sequence of pre-prolactin and establishing sequence homology with growth hormone, consistent with evolution from a common ancestral gene. The coding sequence predicts a signal peptide and mature hormone structure.","method":"cDNA cloning and nucleotide sequencing from pituitary prolactinoma mRNA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original sequence determination, foundational structural characterization","pmids":["6260780"],"is_preprint":false},{"year":1981,"finding":"The human prolactin gene was mapped to chromosome 6, distinct from the chromosomal locations of growth hormone and chorionic somatomammotropin genes, using somatic cell hybrid analysis.","method":"Somatic cell hybrid panel analysis with Southern blotting","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — direct chromosomal mapping with multiple hybrid lines","pmids":["7221563"],"is_preprint":false},{"year":1984,"finding":"The human PRL gene was isolated, shown to be a single-copy gene of ~10 kb containing four introns, three of which interrupt the coding sequence at positions conserved with GH and PRL genes, and the transcription origin was determined by S1 mapping.","method":"Genomic library screening, restriction mapping, DNA sequencing, S1 nuclease mapping","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — direct structural characterization of genomic locus with multiple orthogonal methods","pmids":["6325171"],"is_preprint":false},{"year":1978,"finding":"Prolactin is synthesized in the rough endoplasmic reticulum (ER) of mammotrophs, rapidly transported to the Golgi (within 5–10 min), and sequentially packaged into immature then mature secretory granules over ~3 hours, with progressive ~20–150-fold concentration along the transport route.","method":"Quantitative electron microscopic autoradiography using pulse-chase [3H]leucine labeling of dispersed rat pituitary cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — quantitative ultrastructural pulse-chase defining the complete intracellular transport pathway","pmids":["743954"],"is_preprint":false},{"year":1984,"finding":"In intact female rats, rat GH (but not prolactin itself) induces upregulation of both GH and PRL receptors in the liver in a dose-dependent manner. PRL infusion caused slight downregulation of PRL receptors rather than induction, challenging the concept that PRL auto-induces its own hepatic receptors.","method":"Osmotic minipump infusion of recombinant hormones followed by radioligand binding assay and MgCl2 stripping on liver microsomal membranes","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — rigorous in vivo dose-response with appropriate controls and multiple hormone comparisons","pmids":["6325135"],"is_preprint":false},{"year":1986,"finding":"Ovine PRL and dopamine inhibit basal PRL release from the same subpopulation of rat mammotrophs, but by separate intracellular mechanisms: chloroquine (a lysosomotropic agent) reversed dopamine inhibition but not PRL-mediated inhibition, indicating distinct pathways converging on the same cells.","method":"Reverse hemolytic plaque assay on dispersed rat pituitary cells with pharmacological inhibitors","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — single-cell functional assay with pharmacological dissection of two inhibitory mechanisms","pmids":["3093192"],"is_preprint":false},{"year":1986,"finding":"Antiidiotypic antibodies raised against anti-PRL antibodies specifically bind to PRL receptor-rich membrane preparations and competitively inhibit [125I]-PRL binding to its receptor, demonstrating that anti-PRL idiotypes share structural determinants with the PRL receptor binding site.","method":"Affinity chromatography purification of antibodies, [125I]-Protein A precipitation binding assay, competitive inhibition assays on tissue membrane preparations","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 — indirect binding assay establishing structural mimicry between receptor and anti-hormone antibody idiotypes","pmids":["3002768"],"is_preprint":false},{"year":1988,"finding":"In rat fetal pituitary, PRL mRNA (detectable from fetal day 18) is present at levels disproportionately higher than PRL protein content, and dopamine promotes PRL storage post-birth; in vitro, newborn pituitary cells store PRL when cultured with dopamine, indicating dopamine regulates PRL accumulation/storage rather than synthesis at the neonatal stage.","method":"Immunocytochemistry, in situ hybridization, cDNA probe hybridization quantification, in vitro dopamine treatment of primary pituitary cells, radioimmunoassay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in one study, but single laboratory","pmids":["2464129"],"is_preprint":false},{"year":1990,"finding":"Human PRL gene expression in extrapituitary sites (decidua and lymphoblasts) is initiated from an alternative promoter located ~6 kb upstream of the pituitary-specific start site, producing mRNA with a distinct 5'-noncoding exon; this extrapituitary transcript encodes the same mature PRL protein.","method":"cDNA cloning, 5'-UTR sequencing, S1 mapping, Northern blot analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct sequence determination and promoter mapping establishing alternative transcription start site","pmids":["1697858"],"is_preprint":false},{"year":1992,"finding":"PRL receptor (PRL-R) mRNA, including both long and short isoforms, is expressed in the rat anterior pituitary, medial basal hypothalamus, and posterior pituitary — in addition to peripheral tissues — as demonstrated by RT-PCR, indicating PRL can feed back on its own secretion through receptors at both hypothalamic and pituitary levels.","method":"Reverse transcription-PCR with isoform-specific primers on RNA from multiple brain and peripheral tissues","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific PCR with tissue panel; functional implication supported by known physiology but localization alone","pmids":["1537321"],"is_preprint":false},{"year":1994,"finding":"The extrapituitary PRL promoter (decidual/lymphoid promoter) driving PRL gene expression in endometrial stroma and lymphocytes is independent of Pit-1 (the pituitary-specific transcription factor) and is not directly controlled by progesterone receptor, but is activated by cAMP signaling in endometrial stromal cells.","method":"Transfection of promoter-reporter constructs (3 kb 5'-flanking dPRL) into multiple cell types, Pit-1 co-expression experiments, pharmacological cAMP stimulation","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — multiple cell lines, promoter deletion/mutation analysis, pharmacological approach; Pit-1 independence confirmed by overexpression","pmids":["8015553"],"is_preprint":false},{"year":1994,"finding":"The crystal structure of hGH bound to the extracellular domain of the human PRL receptor (hPRLR) at 1:1 stoichiometry was solved, revealing the structural basis for how hGH binds to two distinct receptor types (hGHR and hPRLR) through overlapping but non-identical receptor-binding surfaces.","method":"X-ray crystallography of hGH–hPRLR extracellular domain complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with direct structural insight into receptor binding specificity","pmids":["7984244"],"is_preprint":false},{"year":1996,"finding":"Human PRL binds Zn²⁺ at a site involving histidine-27 (H27); the H27A mutant shows greatly reduced Zn²⁺ binding but retains normal biological activity and fold, demonstrating that Zn²⁺ binding to the high-affinity site is not required for receptor activation but promotes concentration-dependent self-association/aggregation of PRL.","method":"65Zn binding assays, Scatchard analysis, Nb2 cell bioassay, circular dichroism spectroscopy, dynamic light scattering, sedimentation equilibrium analysis","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 — site-directed mutagenesis combined with multiple biophysical assays and functional validation","pmids":["8833655"],"is_preprint":false},{"year":1996,"finding":"Chimeric PRL receptors bearing the transmembrane/cytoplasmic domains of IL-2Rβ or βc cytokine receptor subunits transduce PRL signals through Jak1 and Jak2 respectively, both leading to Stat5 tyrosine phosphorylation, DNA binding, and β-casein promoter activation, demonstrating that distinct cytoplasmic domains converge on the same Stat5-dependent transcriptional output and that Stat5 activation is not dependent on a specific JAK kinase.","method":"Stably transfected CHO cells expressing chimeric receptors, Western blotting for phospho-Jak1/Jak2/Stat5, EMSA with LHRR probe, luciferase reporter assay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — chimeric receptor approach with multiple orthogonal readouts in stable cell lines","pmids":["8721989"],"is_preprint":false},{"year":1997,"finding":"During in vivo lactogenesis in rats, PRL activates JAK2 and STAT5 in mammary gland (but not in liver) despite the PRL receptor being constitutively associated with JAK2 in both tissues. The long-form PRL-R predominates in mammary gland, while the short form is abundant in liver and may form inactive heterodimers with the long form, explaining tissue-specific signal activation.","method":"In vivo PRL injection in ovario-hysterectomized rats, immunoprecipitation/Western blot for phospho-JAK2 and phospho-PRLR, EMSA for STAT5 binding using β-casein probe, quantitative RT-PCR for receptor isoforms","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 — in vivo model with reciprocal Co-IP and EMSA, tissue-specific comparison with quantitative isoform analysis","pmids":["9314595"],"is_preprint":false},{"year":1997,"finding":"Anti-PRL IgG autoantibodies form non-covalent complexes with 23 kDa monomeric PRL (which retains full bioactivity in vitro), and the IgG-PRL complex is cleared more slowly from rat circulation than free PRL, explaining macroprolactinemia as a result of delayed metabolic clearance rather than increased secretion.","method":"Enzyme immunoassay, Nb2-cell bioassay, gel chromatography, affinity chromatography, SDS-PAGE under non-reducing conditions, pharmacokinetic clearance studies in anesthetized rats","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods plus in vivo clearance studies, establishing mechanism of macroprolactinemia","pmids":["9284753"],"is_preprint":false},{"year":1998,"finding":"PRL receptor (PRLR) knockout mice display: infertility in homozygous females (due to ovulation of premeiotic oocytes, reduced fertilization, lack of implantation), near-complete failure to lactate in heterozygous females after first pregnancy, and reduced islet/beta-cell function, establishing the physiological roles of PRL/lactogen signaling through the PRLR in reproductive function and lactation.","method":"Targeted gene deletion in mice (PRLR knockout), phenotypic analysis of reproductive outcomes, histology, hormone assays","journal":"Endocrine reviews","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function genetic model with multiple defined phenotypic readouts; foundational review summarizing original KO studies","pmids":["9626554"],"is_preprint":false},{"year":2000,"finding":"The C-terminal cytoplasmic domain of the PRL receptor exerts a negative regulatory role on PRL-induced MAPK (ERK) activation; MAPK activation by PRL requires both MEK-dependent and PI3K-dependent pathways, and the negative regulation by the C-terminal domain involves tyrosine phosphatases and serine/threonine phosphatases recruited by the last 141 residues.","method":"Transient transfection of PRL-R cytoplasmic domain deletion/truncation mutants in CHO cells, pharmacological inhibitors (pervanadate, PAO, okadaic acid, MEK inhibitor, PI3K inhibitor), Western blot for phospho-ERK","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic receptor mutant analysis with pharmacological dissection; single laboratory","pmids":["10687859"],"is_preprint":false},{"year":2001,"finding":"Dopamine suppresses PRL secretion from pituitary lactotrophs by binding D2 dopamine receptors coupled to membrane ion channels and G proteins, controlling calcium fluxes and activating intracellular signaling pathways, while also suppressing PRL gene expression and lactotroph proliferation. PRL homeostasis is determined by this inhibitory dopamine tone balanced against multiple stimulatory factors.","method":"Review integrating pharmacological, transgenic animal, and clinical studies; calcium flux measurements, receptor characterization, gene expression assays","journal":"Endocrine reviews","confidence":"High","confidence_rationale":"Tier 2 — mechanistic review of extensively replicated findings across multiple labs and model systems","pmids":["11739329"],"is_preprint":false},{"year":2001,"finding":"S179D-human PRL (designed to mimic phospho-S179 PRL) acts as an agonist, not an antagonist, at the human PRL receptor: it stimulates Nb2 cell proliferation, T-47D cell proliferation, transcriptional activation of lactogenic response element reporters, and activates JAK/STAT and MAPK pathways, albeit with slightly reduced affinity due to local alteration of receptor binding site 1.","method":"Nb2 lymphoma cell proliferation bioassay, T-47D human mammary tumor cell proliferation assay, lactogenic hormone response element-luciferase reporter assay, Western blot for JAK2/STAT5/MAPK phosphorylation","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays and signaling readouts; directly refutes prior claims of antagonism","pmids":["11517174"],"is_preprint":false},{"year":2002,"finding":"PRL-receptor-deficient (PRLR KO) mice exhibit 26–42% reductions in islet density and beta-cell mass from as early as 3 weeks of age, with reduced pancreatic insulin mRNA, lower islet insulin content, blunted glucose-stimulated insulin secretion both in vivo and in vitro, and impaired glucose tolerance, establishing a physiological role for lactogenic hormones in islet development and beta-cell function.","method":"PRLR knockout mouse model, morphometric analysis of islet density and beta-cell mass, pancreatic insulin mRNA quantification, static and dynamic glucose-stimulated insulin secretion assays, intraperitoneal glucose tolerance test","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function model with multiple quantitative phenotypic readouts across sexes and ages","pmids":["11897695"],"is_preprint":false},{"year":2002,"finding":"PRL significantly increases proliferation of mammary carcinoma cells and upregulates cyclin D1 mRNA/protein levels via transcriptional activation of the cyclin D1 promoter through the JAK2/STAT5 pathway. PRL-induced Stat5a and Stat5b bind as a heterodimer to a distal GAS site in the cyclin D1 promoter; disruption of this distal GAS site abolishes PRL-induced promoter activity.","method":"Cell proliferation assays, cyclin D1 protein immunoblot, actinomycin D transcription block, cyclin D1 promoter-luciferase reporter assay in CHO cells, EMSA demonstrating STAT5 binding to GAS sites, co-immunoprecipitation of STAT5a/5b heterodimers from nuclear extracts","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (reporter assay, EMSA, Co-IP) with specific promoter element identification","pmids":["11923474"],"is_preprint":false},{"year":2003,"finding":"PRL directly inhibits lipoprotein lipase (LPL) activity in human white adipose tissue to ~31% of control via functional PRL receptors (long and intermediate isoforms expressed in adipose tissue), demonstrating a direct metabolic action of PRL on lipid metabolism in humans.","method":"RT-PCR/Southern blot and immunoblot for PRLR isoforms in human adipose tissue, in vitro culture of human adipose tissue with PRL/GH/cortisol, LPL enzyme activity assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — receptor expression confirmed plus functional enzymatic assay in primary human tissue","pmids":["12679477"],"is_preprint":false},{"year":2005,"finding":"Human pituitary PRL is phosphorylated at serine 194 and serine 163; serine 163 is dephosphorylated in serum PRL. Acidic PRL isoforms (with distinct pI) are enriched in macroprolactinemic patients with anti-PRL autoantibodies and may contribute to chronic antigen stimulation (IgG4-predominant response).","method":"Western blot, mass spectrometry, two-dimensional electrophoresis, enzyme immunoassay for IgG subclasses","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry identification of phosphorylation sites on human PRL with biochemical validation","pmids":["15687336"],"is_preprint":false},{"year":2006,"finding":"Human scalp hair follicles express both PRL and PRL receptors at mRNA and protein level, and treatment of organ-cultured human hair follicles with high-dose PRL (400 ng/ml) inhibits hair shaft elongation, promotes premature catagen development, reduces keratinocyte proliferation, and increases apoptosis, demonstrating PRL acts as an autocrine/paracrine catagen-promoting factor in human skin.","method":"RT-PCR, immunohistology for PRL and PRL-R, organ culture of human scalp hair follicles with PRL, Ki-67/TUNEL immunohistomorphometry","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — functional organ culture with quantitative cellular readouts; both receptor expression and functional response demonstrated","pmids":["16507890"],"is_preprint":false},{"year":2007,"finding":"In mice with cardiomyocyte-specific STAT3 deletion, enhanced cardiac cathepsin D (CD) activity cleaves full-length prolactin into an antiangiogenic/proapoptotic 16 kDa N-terminal fragment that impairs cardiac capillary network and function, causing postpartum cardiomyopathy (PPCM). Bromocriptine (prolactin secretion inhibitor) prevents PPCM, and forced cardiac generation of 16 kDa PRL recapitulates the PPCM phenotype.","method":"Cardiomyocyte-specific Stat3 knockout mice, cathepsin D activity assay, Western blot for 16 kDa PRL fragment, bromocriptine treatment, forced myocardial 16 kDa PRL overexpression, cardiac function/capillary network assessment, measurement of serum CD and 16 kDa PRL in human PPCM patients","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — mechanistic reconstitution (forced 16 kDa PRL expression recapitulates phenotype), genetic model, and pharmacological intervention; multiple orthogonal approaches validated in human samples","pmids":["17289576"],"is_preprint":false},{"year":2008,"finding":"The PRL/JAK2/STAT5 signaling pathway is enhanced in estrogen receptor-positive (ER+) breast cancer cells (T47D, MCF7) compared with ER-negative lines, as measured by a highly sensitive pGL4-CISH luciferase reporter; overexpression of STAT5 further amplifies PRL-driven CISH reporter activation.","method":"Luciferase reporter assay (pGL4-CISH) in multiple cell lines, STAT5 overexpression, comparison across ER+ and ER- cell lines","journal":"BMC biotechnology","confidence":"Medium","confidence_rationale":"Tier 3 — reporter assay establishing ER-status-dependent PRL/STAT5 signaling differences; single method","pmids":["18254957"],"is_preprint":false},{"year":2012,"finding":"Prolactin receptor activation and signaling involve: (1) sequential two-step binding where site 1 on PRL binds one receptor molecule, then site 2 binds a second receptor to form a 1:2 (PRL:PRLR) homodimer; (2) receptor dimerization activates associated JAK2 kinase (no intrinsic kinase domain in PRLR), leading to phosphorylation of JAK2 and the receptor; (3) downstream activation of STAT5, Ras/Raf/MAPK, IRS-1/PI3K, SHP-2, PLCγ, and PKC pathways. Three human hormones (PRL, GH, placental lactogen) can activate the PRLR through structurally distinct mechanisms.","method":"Comprehensive mechanistic review integrating structural, biochemical, and genetic studies","journal":"Endocrine reviews","confidence":"High","confidence_rationale":"Tier 1-2 — synthesis of crystallographic, mutagenesis, and biochemical data establishing the canonical receptor activation mechanism","pmids":["22577091"],"is_preprint":false},{"year":2013,"finding":"The 16 kDa N-terminal PRL fragment induces microRNA-146a (miR-146a) expression in endothelial cells (ECs), which attenuates angiogenesis by downregulating NRAS. 16K PRL stimulates secretion of miR-146a-loaded exosomes from ECs; these exosomes are absorbed by cardiomyocytes, raising miR-146a levels and decreasing metabolic activity and expression of Erbb4, Notch1, and Irak1, thereby contributing to PPCM pathogenesis.","method":"miRNA expression profiling, luciferase reporter for NRAS 3'UTR, exosome isolation and transfer experiments, cardiomyocyte-specific Stat3 KO mouse model, locked nucleic acid/antago-miR treatment, measurement of miR-146a in PPCM patient plasma and hearts","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway from 16K PRL to miR-146a to cardiomyocyte dysfunction, validated in mouse model and human samples with functional rescue","pmids":["23619365"],"is_preprint":false},{"year":2013,"finding":"Stiff collagen matrices shift prolactin signaling in luminal breast cancer cells from STAT5-mediated physiological outcomes to SRC family kinase-dependent FAK phosphorylation (pY925), FAK-GRB2 association, and ERK1/2 activation, promoting matrix metalloproteinase-dependent invasion. Co-localization of PRL receptors with integrin-activated FAK increases in stiff matrices, implicating altered spatial receptor organization.","method":"Three-dimensional collagen I matrix culture with defined stiffness, Western blot for phospho-STAT5/FAK/ERK, matrix metalloproteinase invasion assay, pharmacological SRC inhibitors, immunofluorescence co-localization of PRLR and FAK","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — controlled ECM stiffness system with multiple signaling readouts and pharmacological validation; single laboratory","pmids":["23530035"],"is_preprint":false},{"year":2021,"finding":"A heterozygous stop-gain mutation in PRL exon 5 (p.Arg220Ter, c.658C>T) causes familial prolactin deficiency and alactogenesis. Transfection of the mutant PRL produces normal intracellular prolactin levels but fails to secrete immunoactive or bioactive prolactin; deletion of the terminal cysteine (p.Lys218Ter) also impairs secretion and cannot be rescued by removing the penultimate cysteine, indicating the C-terminal disulfide bond is essential for PRL secretion.","method":"Sanger sequencing of PRL exons, transfection of wild-type and mutant PRL constructs, conditioned medium immunoassay for secreted PRL, Nb2-cell bioassay for bioactive PRL","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — functional mutagenesis in transfected cells with paired secretion and bioactivity assays, validated in familial human mutation","pmids":["33770166"],"is_preprint":false}],"current_model":"Prolactin (PRL) is a single-copy pituitary hormone (chromosome 6) that is synthesized in the ER of lactotrophs, packaged via Golgi into secretory granules, and secreted under tonic inhibition by dopamine acting through D2 receptors/calcium flux; its secretion requires intact C-terminal disulfide bonds. PRL binds its receptor (PRLR) through a sequential two-step mechanism forming a 1:2 ligand-receptor homodimer that activates constitutively associated JAK2, leading to receptor and JAK2 phosphorylation, STAT5 dimerization and nuclear translocation (driving target genes such as cyclin D1 and β-casein), and parallel activation of Ras/MAPK and PI3K pathways; the C-terminal cytoplasmic domain of the PRLR exerts negative feedback on MAPK activation via phosphatase recruitment. Extrapituitary PRL expression uses an alternative upstream promoter activated by cAMP independently of Pit-1. Pituitary PRL is phosphorylated at Ser-163/Ser-194, and cathepsin D can cleave full-length PRL into an antiangiogenic 16 kDa fragment that drives postpartum cardiomyopathy via exosomal miR-146a transfer to cardiomyocytes. PRL also directly inhibits lipoprotein lipase in adipose tissue, promotes catagen in hair follicles, and is required (via lactogenic signaling through the PRLR) for normal beta-cell mass and islet development."},"narrative":{"teleology":[{"year":1978,"claim":"Defining the intracellular biosynthetic route of PRL—from ER synthesis through Golgi packaging to mature secretory granules—established the timeline and concentration steps underlying regulated hormone secretion from lactotrophs.","evidence":"Quantitative EM autoradiography with pulse-chase [³H]leucine labeling in dispersed rat pituitary cells","pmids":["743954"],"confidence":"High","gaps":["Molecular machinery controlling granule maturation and sorting was not identified","No direct comparison between constitutive and regulated secretory pathways"]},{"year":1981,"claim":"Cloning and sequencing the human PRL cDNA and mapping the gene to chromosome 6 resolved the primary structure of pre-prolactin and established PRL as a single-locus gene distinct from GH/CS, providing the molecular foundation for all subsequent functional studies.","evidence":"cDNA cloning from pituitary prolactinoma mRNA and somatic cell hybrid chromosomal mapping","pmids":["6260780","7221563"],"confidence":"High","gaps":["Three-dimensional structure of PRL itself was not yet determined","Receptor identity and binding mode remained unknown"]},{"year":1984,"claim":"Full genomic characterization revealed PRL as a single-copy ~10 kb gene with conserved intron–exon organization shared with GH, solidifying the gene duplication model and defining the transcriptional start site.","evidence":"Genomic library screening, restriction mapping, DNA sequencing, S1 nuclease mapping","pmids":["6325171"],"confidence":"High","gaps":["Regulatory elements controlling pituitary-specific expression were not mapped","Alternative promoter usage was unknown"]},{"year":1986,"claim":"Demonstrating that PRL and dopamine inhibit PRL release from the same lactotroph subpopulation via distinct intracellular mechanisms resolved a key question about whether autocrine PRL feedback and dopaminergic inhibition are parallel or convergent pathways.","evidence":"Reverse hemolytic plaque assay on single rat pituitary cells with chloroquine dissection","pmids":["3093192"],"confidence":"High","gaps":["Molecular identity of the PRL autocrine receptor pathway in lactotrophs was not defined","Signaling intermediates downstream of each inhibitory mechanism were not characterized"]},{"year":1990,"claim":"Discovery of an alternative upstream promoter ~6 kb 5' of the pituitary start site, producing the same mature PRL protein in decidua and lymphoblasts, explained how extrapituitary PRL expression is achieved independently of the pituitary transcription factor Pit-1.","evidence":"cDNA cloning, 5'-UTR sequencing, S1 mapping, and Northern blot from decidual and lymphoblast RNA","pmids":["1697858"],"confidence":"High","gaps":["Transcription factors driving the extrapituitary promoter were not yet identified"]},{"year":1994,"claim":"Showing that the extrapituitary PRL promoter is activated by cAMP independently of Pit-1 and progesterone receptor identified the signaling pathway controlling decidual/lymphoid PRL expression and distinguished it mechanistically from pituitary regulation.","evidence":"Promoter-reporter transfection in multiple cell types with Pit-1 co-expression and cAMP stimulation","pmids":["8015553"],"confidence":"High","gaps":["Specific cAMP-responsive transcription factors binding the extrapituitary promoter were not identified","In vivo validation of cAMP requirement was lacking"]},{"year":1994,"claim":"The crystal structure of hGH bound to the hPRLR extracellular domain revealed the structural basis for sequential receptor engagement and cross-reactivity between GH and PRL receptor families, establishing the two-site binding paradigm.","evidence":"X-ray crystallography of hGH–hPRLR ECD complex","pmids":["7984244"],"confidence":"High","gaps":["A structure of PRL itself bound to PRLR was not yet available","Transmembrane and intracellular conformational changes upon dimerization were unknown"]},{"year":1996,"claim":"Mutagenesis of the Zn²⁺-binding site (H27A) demonstrated that Zn²⁺ promotes PRL self-association but is dispensable for receptor activation, separating storage/aggregation properties from signaling function.","evidence":"⁶⁵Zn binding, Scatchard analysis, Nb2 bioassay, CD spectroscopy, and sedimentation equilibrium on WT and H27A PRL","pmids":["8833655"],"confidence":"High","gaps":["Physiological significance of Zn²⁺-dependent aggregation in pituitary granules was not tested in vivo"]},{"year":1996,"claim":"Chimeric PRL receptor experiments demonstrated that different cytoplasmic domains (from IL-2Rβ or βc) all converge on STAT5 activation and β-casein transcription, establishing STAT5 as the obligate downstream effector regardless of the specific JAK kinase engaged.","evidence":"Stable CHO cells expressing chimeric PRLR with IL-2Rβ or βc cytoplasmic domains; phospho-JAK/STAT Western blot, EMSA, β-casein reporter","pmids":["8721989"],"confidence":"High","gaps":["Relative contributions of STAT5a vs. STAT5b to specific target gene activation were not resolved"]},{"year":1997,"claim":"Tissue-specific signaling outcomes of PRL were explained by showing that mammary gland (long-form PRLR dominant) activates JAK2/STAT5 in vivo while liver (short-form PRLR abundant) does not, implicating inactive heterodimers as a tissue-selective gating mechanism.","evidence":"In vivo PRL injection in ovario-hysterectomized rats with tissue-specific Co-IP, EMSA, and quantitative RT-PCR for receptor isoforms","pmids":["9314595"],"confidence":"High","gaps":["Direct demonstration that short/long heterodimers are signaling-incompetent was not provided","Mechanism preventing JAK2 activation in heterodimers was unresolved"]},{"year":1998,"claim":"PRLR knockout mice established the non-redundant in vivo requirements for PRL signaling in female fertility, lactation, and pancreatic islet development, providing the definitive loss-of-function phenotypic framework.","evidence":"PRLR gene-targeted deletion in mice with reproductive, lactation, and islet phenotyping","pmids":["9626554"],"confidence":"High","gaps":["Individual contributions of PRL vs. placental lactogen signaling through PRLR were not distinguished","CNS-mediated behavioral phenotypes were incompletely characterized"]},{"year":2000,"claim":"Identification of a negative regulatory role for the PRLR C-terminal domain on MAPK activation—through recruitment of tyrosine and serine/threonine phosphatases—revealed an intrinsic feedback mechanism that limits mitogenic signaling.","evidence":"PRLR truncation/deletion mutants in CHO cells with pharmacological phosphatase inhibitors and phospho-ERK Western blot","pmids":["10687859"],"confidence":"Medium","gaps":["Specific phosphatases recruited to the C-terminal domain were not identified","In vivo significance of this feedback in mammary tissue was not tested"]},{"year":2002,"claim":"PRL was shown to transcriptionally activate cyclin D1 through a STAT5a/5b heterodimer binding a distal GAS element in the cyclin D1 promoter, directly linking PRL–STAT5 signaling to cell cycle progression in mammary carcinoma cells.","evidence":"Cyclin D1 promoter-luciferase reporters, EMSA with STAT5-specific supershifts, STAT5a/5b co-IP from nuclear extracts, proliferation assays in mammary carcinoma cells","pmids":["11923474"],"confidence":"High","gaps":["Whether STAT5 heterodimer vs. homodimer usage differs between normal and malignant mammary cells was not addressed"]},{"year":2002,"claim":"Quantitative analysis of PRLR KO pancreata demonstrated that PRL/lactogenic signaling is required for normal islet density, beta-cell mass, and glucose-stimulated insulin secretion from early postnatal life, extending PRL's physiological roles beyond reproduction.","evidence":"PRLR knockout mouse morphometry, insulin mRNA quantification, static/dynamic insulin secretion assays, glucose tolerance testing","pmids":["11897695"],"confidence":"High","gaps":["Whether PRL acts directly on beta cells or indirectly through islet vasculature/stroma was unresolved","Compensatory mechanisms from other growth factors were not excluded"]},{"year":2003,"claim":"Demonstration that PRL directly inhibits lipoprotein lipase activity in human white adipose tissue via functional PRLR isoforms established a direct metabolic action on lipid partitioning.","evidence":"LPL enzyme activity assay in PRL-treated human adipose tissue explants with PRLR expression confirmed by RT-PCR and immunoblot","pmids":["12679477"],"confidence":"High","gaps":["Signaling pathway from PRLR to LPL inhibition was not delineated","In vivo metabolic consequences in humans were not measured"]},{"year":2005,"claim":"Mass spectrometric identification of Ser-163 and Ser-194 phosphorylation on human pituitary PRL, with Ser-163 dephosphorylated in circulating PRL, defined post-translational modifications that distinguish stored and secreted hormone forms.","evidence":"Mass spectrometry, 2D electrophoresis, Western blot on pituitary and serum PRL","pmids":["15687336"],"confidence":"High","gaps":["Kinase(s) responsible for Ser-163/Ser-194 phosphorylation were not identified","Functional consequences of each phosphorylation event on receptor binding or bioactivity were not resolved"]},{"year":2006,"claim":"Showing that human hair follicles express both PRL and PRLR and that exogenous PRL induces premature catagen established PRL as an autocrine/paracrine catagen-promoting factor in human skin.","evidence":"RT-PCR and immunohistology for PRL/PRLR in scalp follicles; organ culture with PRL and Ki-67/TUNEL morphometry","pmids":["16507890"],"confidence":"High","gaps":["Intracellular signaling pathway mediating catagen induction in follicular keratinocytes was not identified","Relative contribution of locally produced vs. circulating PRL was unknown"]},{"year":2007,"claim":"Discovery that cathepsin D cleaves PRL into a 16 kDa antiangiogenic fragment in the context of cardiac STAT3 deficiency, and that this fragment is both necessary and sufficient for peripartum cardiomyopathy (PPCM), identified a pathogenic proteolytic product of PRL and established a causal mechanism for PPCM.","evidence":"Cardiomyocyte-specific Stat3 KO mice, cathepsin D activity assay, forced 16 kDa PRL expression, bromocriptine rescue, human PPCM patient serum analysis","pmids":["17289576"],"confidence":"High","gaps":["Endothelial receptor for 16 kDa PRL was not identified","Whether cathepsin D cleavage occurs intracellularly or extracellularly in the cardiac microenvironment was unclear"]},{"year":2013,"claim":"Elucidation of the 16 kDa PRL → miR-146a → exosome → cardiomyocyte axis provided the intercellular signaling mechanism by which the antiangiogenic PRL fragment damages the myocardium, identifying specific downstream targets (NRAS, Erbb4, Notch1, Irak1) in cardiomyocytes.","evidence":"miRNA profiling, NRAS 3'UTR luciferase reporter, exosome isolation/transfer, Stat3 KO mouse model, locked nucleic acid rescue, human PPCM plasma miR-146a measurement","pmids":["23619365"],"confidence":"High","gaps":["Mechanism by which 16 kDa PRL induces miR-146a transcription in endothelial cells was not defined","Therapeutic window for anti-miR-146a or bromocriptine intervention was not established"]},{"year":2021,"claim":"A human stop-gain mutation (p.Arg220Ter) causing familial prolactin deficiency and alactogenesis demonstrated that the C-terminal disulfide bond is essential for PRL secretion, linking structural integrity to the secretory pathway and establishing a Mendelian form of PRL deficiency.","evidence":"Sanger sequencing, transfection of WT/mutant PRL, conditioned medium immunoassay and Nb2 bioassay for secretion","pmids":["33770166"],"confidence":"High","gaps":["Mechanism by which C-terminal disulfide bond disruption blocks secretion (ER retention vs. degradation) was not resolved","Prevalence of PRL mutations in idiopathic lactation failure is unknown"]},{"year":null,"claim":"Key unresolved questions include: the atomic structure of the PRL–PRLR ternary complex, the identity of kinases phosphorylating Ser-163/Ser-194, the endothelial receptor mediating 16 kDa PRL effects, and whether PRL acts directly on pancreatic beta cells or through islet accessory cells.","evidence":"","pmids":[],"confidence":"Low","gaps":["No PRL:PRLR ternary complex structure available","Kinases for Ser-163/Ser-194 unidentified","16 kDa PRL endothelial receptor unknown","Direct vs. indirect beta-cell action unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[11,19,21,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[22,24,25]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,15,30]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,14,17,19,21,27]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,23,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,28]}],"complexes":[],"partners":["PRLR","JAK2","STAT5A","STAT5B","CTSD"],"other_free_text":[]},"mechanistic_narrative":"Prolactin (PRL) is a pituitary-derived peptide hormone that orchestrates lactation, reproductive function, metabolic homeostasis, and tissue remodeling through activation of the JAK2–STAT5 signaling axis and parallel MAPK and PI3K pathways. PRL is synthesized in the rough ER of lactotrophs, trafficked through the Golgi into secretory granules under tonic inhibitory control by dopamine acting via D2 receptors [PMID:743954, PMID:11739329]; its secretion requires an intact C-terminal disulfide bond, as demonstrated by a human loss-of-function mutation (p.Arg220Ter) causing familial prolactin deficiency and alactogenesis [PMID:33770166]. PRL binds the PRL receptor in a sequential 1:2 stoichiometry that activates constitutively associated JAK2, driving STAT5a/5b-dependent transcription of targets including cyclin D1 and β-casein, while the receptor's C-terminal cytoplasmic domain recruits phosphatases that negatively regulate MAPK output [PMID:22577091, PMID:11923474, PMID:10687859]. Extrapituitary PRL expression from a Pit-1-independent upstream promoter activated by cAMP enables autocrine/paracrine functions in decidua, lymphocytes, and hair follicles, and cathepsin D cleavage of full-length PRL generates a 16 kDa antiangiogenic fragment that drives peripartum cardiomyopathy through exosomal miR-146a transfer to cardiomyocytes [PMID:8015553, PMID:17289576, PMID:23619365]."},"prefetch_data":{"uniprot":{"accession":"P01236","full_name":"Prolactin","aliases":[],"length_aa":227,"mass_kda":25.9,"function":"Prolactin acts primarily on the mammary gland by promoting lactation","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01236/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRL","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRL","total_profiled":1310},"omim":[{"mim_id":"620890","title":"GROWTH HORMONE-REGULATED TBC PROTEIN 1; GRTP1","url":"https://www.omim.org/entry/620890"},{"mim_id":"618702","title":"SHORT STATURE AND MICROCEPHALY WITH GENITAL ANOMALIES; SSMGA","url":"https://www.omim.org/entry/618702"},{"mim_id":"618573","title":"HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 7; CHNG7","url":"https://www.omim.org/entry/618573"},{"mim_id":"618160","title":"PITUITARY HORMONE DEFICIENCY, COMBINED OR ISOLATED, 7; CPHD7","url":"https://www.omim.org/entry/618160"},{"mim_id":"618096","title":"PREMATURE OVARIAN FAILURE 15; POF15","url":"https://www.omim.org/entry/618096"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"pituitary gland","ntpm":58560.7}],"url":"https://www.proteinatlas.org/search/PRL"},"hgnc":{"alias_symbol":["pPRL"],"prev_symbol":[]},"alphafold":{"accession":"P01236","domains":[{"cath_id":"1.20.1250.10","chopping":"42-86_94-222","consensus_level":"high","plddt":93.0875,"start":42,"end":222}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01236","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01236-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01236-F1-predicted_aligned_error_v6.png","plddt_mean":85.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRL","jax_strain_url":"https://www.jax.org/strain/search?query=PRL"},"sequence":{"accession":"P01236","fasta_url":"https://rest.uniprot.org/uniprotkb/P01236.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01236/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01236"}},"corpus_meta":[{"pmid":"11739329","id":"PMC_11739329","title":"Dopamine as a prolactin (PRL) inhibitor.","date":"2001","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11739329","citation_count":712,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8196618","id":"PMC_8196618","title":"PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8196618","citation_count":247,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17409395","id":"PMC_17409395","title":"PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17409395","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11897695","id":"PMC_11897695","title":"Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11897695","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18224294","id":"PMC_18224294","title":"PRL PTPs: mediators and markers of cancer progression.","date":"2008","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18224294","citation_count":174,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16540666","id":"PMC_16540666","title":"PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16540666","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2202721","id":"PMC_2202721","title":"The sec and prl genes of Escherichia coli.","date":"1990","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/2202721","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20609352","id":"PMC_20609352","title":"PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.","date":"2010","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/20609352","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11923474","id":"PMC_11923474","title":"PRL activates the cyclin D1 promoter via the Jak2/Stat pathway.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11923474","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21053359","id":"PMC_21053359","title":"PRL-3 phosphatase and cancer metastasis.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21053359","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15263806","id":"PMC_15263806","title":"Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.","date":"2004","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15263806","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18471976","id":"PMC_18471976","title":"The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18471976","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24632616","id":"PMC_24632616","title":"The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24632616","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9284753","id":"PMC_9284753","title":"Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex.","date":"1997","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9284753","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6325135","id":"PMC_6325135","title":"Rat growth hormone (GH) but not prolactin (PRL) induces both GH and PRL receptors in female rat liver.","date":"1984","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/6325135","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1537321","id":"PMC_1537321","title":"Detection of prolactin receptor (PRL-R) mRNA in the rat hypothalamus and pituitary gland.","date":"1992","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1537321","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17934070","id":"PMC_17934070","title":"Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17934070","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17018620","id":"PMC_17018620","title":"PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018620","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26669864","id":"PMC_26669864","title":"Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26669864","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14643450","id":"PMC_14643450","title":"Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/14643450","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27856537","id":"PMC_27856537","title":"Phosphocysteine in the PRL-CNNM pathway mediates magnesium homeostasis.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27856537","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15571731","id":"PMC_15571731","title":"Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15571731","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23867504","id":"PMC_23867504","title":"Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23867504","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18078820","id":"PMC_18078820","title":"Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18078820","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16472776","id":"PMC_16472776","title":"Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16472776","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18364570","id":"PMC_18364570","title":"Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.","date":"2008","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18364570","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15135076","id":"PMC_15135076","title":"Structure of human PRL-3, the phosphatase associated with cancer metastasis.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15135076","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9314595","id":"PMC_9314595","title":"In vivo study of prolactin (PRL) intracellular signalling during lactogenesis in the rat: JAK/STAT pathway is activated by PRL in the mammary gland but not in the liver.","date":"1997","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9314595","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29770564","id":"PMC_29770564","title":"Physiological and oncogenic roles of the PRL phosphatases.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29770564","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31084703","id":"PMC_31084703","title":"Increased anxiety and decreased sociability induced by paternal deprivation involve the PVN-PrL OTergic pathway.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31084703","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21806020","id":"PMC_21806020","title":"The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21806020","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15788667","id":"PMC_15788667","title":"Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15788667","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16978626","id":"PMC_16978626","title":"mRNA expression patterns for GH, PRL, SL, IGF-I and IGF-II during altered feeding status in rabbitfish, Siganus guttatus.","date":"2006","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16978626","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23572150","id":"PMC_23572150","title":"KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23572150","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30718434","id":"PMC_30718434","title":"Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30718434","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26969161","id":"PMC_26969161","title":"Inhibition of PRL-2·CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26969161","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23929599","id":"PMC_23929599","title":"Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23929599","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22345654","id":"PMC_22345654","title":"An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22345654","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18997816","id":"PMC_18997816","title":"New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18997816","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32918875","id":"PMC_32918875","title":"The Oncogenic PRL Protein Causes Acid Addiction of Cells by Stimulating Lysosomal Exocytosis.","date":"2020","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/32918875","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2464129","id":"PMC_2464129","title":"Discrepancy between prolactin (PRL) messenger ribonucleic acid and PRL content in rat fetal pituitary cells: possible role of dopamine.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2464129","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15912947","id":"PMC_15912947","title":"Up-regulation of Prl, a subtilisin-like protease, during conidiation in the insect pathogen Metarhizium anisopliae.","date":"2005","source":"Mycological research","url":"https://pubmed.ncbi.nlm.nih.gov/15912947","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6325044","id":"PMC_6325044","title":"The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects.","date":"1984","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/6325044","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30498084","id":"PMC_30498084","title":"PRL-3 Promotes Ubiquitination and Degradation of AURKA and Colorectal Cancer Progression via Dephosphorylation of FZR1.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30498084","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7534770","id":"PMC_7534770","title":"Laminin decreases PRL and IGFBP-1 expression during in vitro decidualization of human endometrial stromal cells.","date":"1995","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7534770","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3093192","id":"PMC_3093192","title":"Ovine prolactin (PRL) and dopamine preferentially inhibit PRL release from the same subpopulation of rat mammotropes.","date":"1986","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/3093192","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21765462","id":"PMC_21765462","title":"Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21765462","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11517174","id":"PMC_11517174","title":"S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11517174","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24737397","id":"PMC_24737397","title":"Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.","date":"2014","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24737397","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18096253","id":"PMC_18096253","title":"Characterization of a PRL protein tyrosine phosphatase from Plasmodium falciparum.","date":"2007","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/18096253","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31048465","id":"PMC_31048465","title":"Branch-restricted localization of phosphatase Prl-1 specifies axonal synaptogenesis domains.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31048465","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28011885","id":"PMC_28011885","title":"LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28011885","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18254957","id":"PMC_18254957","title":"Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter.","date":"2008","source":"BMC biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18254957","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15687336","id":"PMC_15687336","title":"Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15687336","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3002768","id":"PMC_3002768","title":"Antiidiotypic antibodies raised against anti-prolactin (PRL) antibodies recognize the PRL receptor.","date":"1986","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/3002768","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23222559","id":"PMC_23222559","title":"The posterior chamber phakic refractive lens (PRL): a review.","date":"2012","source":"Eye (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23222559","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11447212","id":"PMC_11447212","title":"Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11447212","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3002766","id":"PMC_3002766","title":"Prolactin (PRL), follicle-stimulating hormone, and luteinizing hormone are regulators of testicular PRL receptors in golden hamsters.","date":"1986","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/3002766","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23362275","id":"PMC_23362275","title":"Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL).","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23362275","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24686170","id":"PMC_24686170","title":"LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24686170","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23178297","id":"PMC_23178297","title":"PRL-3 activates NF-κB signaling pathway by interacting with RAP1.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23178297","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31207239","id":"PMC_31207239","title":"The Phosphatase PRL-3 Is Involved in Key Steps of Cancer Metastasis.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31207239","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21466710","id":"PMC_21466710","title":"Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21466710","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8833655","id":"PMC_8833655","title":"Properties of human prolactin (PRL) and H27A-PRL, a mutant that does not bind Zn++.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8833655","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17673310","id":"PMC_17673310","title":"Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17673310","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26874360","id":"PMC_26874360","title":"Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.","date":"2016","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26874360","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26975394","id":"PMC_26975394","title":"Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26975394","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25472537","id":"PMC_25472537","title":"Plasticity of the prolactin (PRL) axis: mechanisms underlying regulation of output in female mice.","date":"2015","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/25472537","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9083259","id":"PMC_9083259","title":"Lactogenic hormones of the placenta and pituitary inhibit suckling-induced prolactin (PRL) release but not the ante-partum PRL surge.","date":"1997","source":"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9083259","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27911713","id":"PMC_27911713","title":"Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.","date":"2016","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/27911713","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35036882","id":"PMC_35036882","title":"The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35036882","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21883511","id":"PMC_21883511","title":"DGAT1, GH, GHR, PRL and PRLR polymorphism in water buffalo (Bubalus bubalis).","date":"2011","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/21883511","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23831336","id":"PMC_23831336","title":"Reversible oxidation of PRL family protein-tyrosine phosphatases.","date":"2013","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/23831336","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10960362","id":"PMC_10960362","title":"PRL-1 PTPase expression is developmentally regulated with tissue-specific patterns in epithelial tissues.","date":"2000","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10960362","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28482095","id":"PMC_28482095","title":"PRL-3 promotes telomere deprotection and chromosomal instability.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28482095","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10499878","id":"PMC_10499878","title":"Urethane-induced somatostatin mediated inhibition of gastric acid: reversal by the somatostatin 2 receptor antagonist, PRL-2903.","date":"1999","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10499878","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16133148","id":"PMC_16133148","title":"Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line.","date":"2005","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/16133148","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33770166","id":"PMC_33770166","title":"PRL Mutation Causing Alactogenesis: Insights Into Prolactin Structure and Function Relationships.","date":"2021","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33770166","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19404952","id":"PMC_19404952","title":"The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19404952","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32762057","id":"PMC_32762057","title":"Indel variants within the PRL and GHR genes associated with sheep litter size.","date":"2020","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/32762057","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20352225","id":"PMC_20352225","title":"HLA class II, MICA and PRL gene polymorphisms: the common contribution to the systemic lupus erythematosus development in Czech population.","date":"2010","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/20352225","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10537137","id":"PMC_10537137","title":"Prolactin (PRL)-like protein J, a novel member of the PRL/growth hormone family, is exclusively expressed in maternal decidua.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10537137","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32753957","id":"PMC_32753957","title":"lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32753957","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7635270","id":"PMC_7635270","title":"Immunocytochemical and morphometric study of TSH, PRL, GH, and ACTH cells in Bufo arenarum larvae with inhibited thyroid function.","date":"1995","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7635270","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8581952","id":"PMC_8581952","title":"Immunocytochemical and morphometric study on the changes of TSH, PRL, GH and ACTH cells during the development of Bufo arenarum.","date":"1996","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/8581952","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25535272","id":"PMC_25535272","title":"A prl mutation in SecY suppresses secretion and virulence defects of Listeria monocytogenes secA2 mutants.","date":"2014","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/25535272","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30305722","id":"PMC_30305722","title":"Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30305722","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29378204","id":"PMC_29378204","title":"Glial cells as mediators of protective actions of prolactin (PRL) in the CNS.","date":"2018","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29378204","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8721989","id":"PMC_8721989","title":"Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8721989","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25687758","id":"PMC_25687758","title":"PRL-3 mediates the protein maturation of ULBP2 by regulating the tyrosine phosphorylation of HSP60.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25687758","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30816227","id":"PMC_30816227","title":"Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816227","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19714484","id":"PMC_19714484","title":"Single nucleotide polymorphisms in bovine PRL gene and their associations with milk production traits in Chinese Holsteins.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19714484","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15707601","id":"PMC_15707601","title":"Cloning of duck PRL cDNA and genomic DNA.","date":"2005","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15707601","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32929353","id":"PMC_32929353","title":"PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32929353","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19040419","id":"PMC_19040419","title":"Analysis of molecular determinants of PRL-3.","date":"2008","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19040419","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10687859","id":"PMC_10687859","title":"Effect of PRL on MAPK activation: negative regulatory role of the C-terminal part of the PRL receptor.","date":"2000","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10687859","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19193983","id":"PMC_19193983","title":"Novel SNP of the goat prolactin gene (PRL) associated with cashmere traits.","date":"2009","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19193983","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28068414","id":"PMC_28068414","title":"Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28068414","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25499125","id":"PMC_25499125","title":"Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.","date":"2014","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/25499125","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10701763","id":"PMC_10701763","title":"Increase in prolactin receptor (PRL-R) mRNA level in the mammary gland after hormonal induction of lactation in virgin ewes.","date":"2000","source":"Domestic animal endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10701763","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9626554","id":"PMC_9626554","title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.","date":"1998","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9626554","citation_count":1425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17289576","id":"PMC_17289576","title":"A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17289576","citation_count":645,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23619365","id":"PMC_23619365","title":"MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23619365","citation_count":385,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7984244","id":"PMC_7984244","title":"The X-ray structure of a growth hormone-prolactin receptor complex.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7984244","citation_count":341,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6260780","id":"PMC_6260780","title":"Human prolactin. cDNA structural analysis and evolutionary comparisons.","date":"1981","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6260780","citation_count":277,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8015553","id":"PMC_8015553","title":"Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma.","date":"1994","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8015553","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17785327","id":"PMC_17785327","title":"Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.","date":"2007","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17785327","citation_count":189,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12552091","id":"PMC_12552091","title":"Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12552091","citation_count":174,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"743954","id":"PMC_743954","title":"Intracellular transport and packaging of prolactin: a quantitative electron microscope autoradiographic study of mammotrophs dissociated from rat pituitaries.","date":"1978","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/743954","citation_count":151,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18207134","id":"PMC_18207134","title":"Genes controlling affiliative behavior as candidate genes for autism.","date":"2008","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18207134","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6325171","id":"PMC_6325171","title":"Isolation and characterization of the human prolactin gene.","date":"1984","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/6325171","citation_count":124,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12928232","id":"PMC_12928232","title":"Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia.","date":"2003","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12928232","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21623375","id":"PMC_21623375","title":"Genome-wide association identifies three new susceptibility loci for Paget's disease of bone.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21623375","citation_count":122,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22577091","id":"PMC_22577091","title":"Molecular mechanisms of prolactin and its receptor.","date":"2012","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22577091","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23284291","id":"PMC_23284291","title":"Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23284291","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7221563","id":"PMC_7221563","title":"The prolactin gene is located on chromosome 6 in humans.","date":"1981","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7221563","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12679477","id":"PMC_12679477","title":"Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12679477","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16507890","id":"PMC_16507890","title":"Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16507890","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1697858","id":"PMC_1697858","title":"Human prolactin gene expression. The use of an alternative noncoding exon in decidua and the IM-9-P3 lymphoblast cell line.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1697858","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20734064","id":"PMC_20734064","title":"A large-scale candidate gene association study of age at menarche and age at natural menopause.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20734064","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23530035","id":"PMC_23530035","title":"Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23530035","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19851340","id":"PMC_19851340","title":"Association between obesity and polymorphisms in SEC16B, TMEM18, GNPDA2, BDNF, FAIM2 and MC4R in a Japanese population.","date":"2009","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19851340","citation_count":102,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23333304","id":"PMC_23333304","title":"CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23333304","citation_count":102,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20399783","id":"PMC_20399783","title":"Prolactin, Oxytocin, and the development of paternal behavior across the first six months of fatherhood.","date":"2010","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/20399783","citation_count":98,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48063,"output_tokens":3969,"usd":0.101862},"stage2":{"model":"claude-opus-4-6","input_tokens":7006,"output_tokens":6616,"usd":0.300645},"total_usd":0.830093,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62793,"output_tokens":9178,"usd":0.163024},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11830,"output_tokens":4689,"usd":0.264562}},"stage1_raw":"Looking at these abstracts, I need to identify which papers are about the human/mammalian gene PRL (prolactin) versus the PRL phosphatase family (PRL-1/PRL-2/PRL-3, also known as PTP4A1/PTP4A2/PTP4A3). These are very different proteins. The query is \"PRL\" which is prolactin.\n\nHowever, many papers in this corpus are about \"PRL-1/PRL-2/PRL-3\" phosphatases (phosphatase of regenerating liver), which are a completely different protein family. I need to distinguish:\n- Papers about prolactin (PRL) = the hormone → INCLUDE\n- Papers about PRL-1/PRL-2/PRL-3 phosphatases → these share the \"PRL\" symbol collision but are different proteins\n\nWait - actually, looking more carefully, the PRL phosphatase papers dominate this corpus, and they are mammalian proteins (PTP4A1, PTP4A2, PTP4A3). But the query gene \"PRL\" specifically refers to prolactin in human gene nomenclature (HGNC symbol PRL = prolactin). The PRL-1/2/3 phosphatases have gene names PTP4A1/2/3.\n\nSo I should focus on prolactin (PRL) papers and exclude PRL phosphatase papers as symbol collisions. Let me identify the true prolactin papers and extract mechanistic findings from those.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Dopamine suppresses prolactin secretion by binding to type-2 dopamine receptors on pituitary lactotrophs, inhibiting PRL release through control of calcium fluxes and activation of multiple intracellular signaling pathways, and also suppresses PRL gene expression and lactotroph proliferation.\",\n      \"method\": \"Review synthesizing pharmacological, transgenic animal, and receptor binding studies; dopamine receptor characterization and signal transduction assays\",\n      \"journal\": \"Endocrine reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple labs with pharmacological, genetic, and receptor-level evidence; foundational review with 712 citations\",\n      \"pmids\": [\"11739329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PRL activates the JAK2-STAT5 signaling pathway in mammary gland but not in liver in vivo; the PRL receptor is constitutively associated with JAK2, and upon PRL stimulation in mammary gland, PRL-R and JAK2 become tyrosine phosphorylated and STAT5 is activated to bind a beta-casein promoter element, whereas liver (which predominantly expresses the short PRL-R form) does not respond despite receptor presence.\",\n      \"method\": \"In vivo rat lactogenesis model; immunoprecipitation with anti-PRL-R and anti-JAK2 antibodies; Western blot for phosphorylated proteins; EMSA with beta-casein STAT5-binding probe; quantitative RT-PCR for receptor isoforms\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with multiple orthogonal methods (IP, Western blot, EMSA, RT-PCR); moderate evidence\",\n      \"pmids\": [\"9314595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PRL activates the cyclin D1 promoter predominantly via the JAK2/STAT5 signaling pathway; PRL induces STAT5a and STAT5b to bind a distal GAS site on the cyclin D1 promoter, and STAT5a/5b can interact as a heterodimer in the nucleus following PRL treatment.\",\n      \"method\": \"Cyclin D1 promoter-luciferase reporter assays in CHO cells; EMSA with GAS site probes; immunoprecipitation of nuclear extracts followed by Western blot for STAT5a/5b; actinomycin D transcription inhibition\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay, EMSA, and co-IP with defined mutagenesis of GAS sites; moderate evidence from single lab with multiple methods\",\n      \"pmids\": [\"11923474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Lactogenic hormones (PRL and placental lactogen) acting through the PRL receptor are required for normal islet development, beta-cell mass, pancreatic insulin mRNA levels, islet insulin content, and glucose-stimulated insulin secretion in vivo, as established using PRL receptor-deficient mice.\",\n      \"method\": \"Targeted deletion of PRL receptor (PRLR-knockout mouse); measurements of islet density, beta-cell mass, pancreatic insulin mRNA, islet insulin content, and glucose/insulin tolerance tests in vivo and in vitro\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with multiple quantitative phenotypic readouts; strong evidence\",\n      \"pmids\": [\"11897695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PRL receptor chimeras containing cytoplasmic domains of IL-2Rβ or βc cytokine receptor subunits transduce PRL-induced tyrosine phosphorylation of JAK1 and JAK2 respectively, activate STAT5 DNA-binding activity, and drive transcription of a beta-casein promoter construct, demonstrating that distinct cytoplasmic receptor domains converge on the same STAT5 signaling pathway.\",\n      \"method\": \"Chimeric PRL receptor constructs stably transfected in CHO cells; kinase assays and tyrosine phosphorylation assays; EMSA with LHRR probe; beta-casein promoter-luciferase reporter assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chimeric receptor approach with reporter and EMSA; single lab\",\n      \"pmids\": [\"8721989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Anti-PRL autoantibodies form a noncovalent complex with 23 kDa PRL bound to IgG, and this PRL-IgG complex retains full bioactivity in vitro but is cleared more slowly from circulation than free PRL, causing hyperprolactinemia without clinical symptoms.\",\n      \"method\": \"Enzyme immunoassay, Nb2-bioassay, gel chromatography, affinity chromatography for IgG, SDS-PAGE, and clearance studies in anesthetized rats\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods plus in vivo clearance study; single lab\",\n      \"pmids\": [\"9284753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PRL-induced MAPK activation requires a membrane-proximal cytoplasmic domain of the PRL receptor and depends on both MEK-dependent and PI3K-dependent pathways; the C-terminal region of the PRL receptor exerts a negative regulatory role on MAPK activation, mediated through tyrosine phosphatases and serine/threonine phosphatases.\",\n      \"method\": \"PRL receptor cytoplasmic domain deletion/mutant constructs; pharmacological inhibitors of MEK, PI3K, tyrosine phosphatases (pervanadate, PAO), and serine/threonine phosphatases (okadaic acid); MAPK activation assays\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-deletion mutagenesis combined with pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"10687859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"S179D-human PRL, designed to mimic phosphorylated PRL at serine 179, acts as an agonist (not antagonist) of the PRL receptor, stimulating Nb2 cell proliferation, transcriptional activation via LHRRE-luciferase, and JAK/STAT and MAPK pathway activation, with slightly reduced affinity due to alteration of receptor binding site 1.\",\n      \"method\": \"Nb2 cell proliferation bioassay; LHRRE-luciferase transcriptional reporter; JAK/STAT and MAPK signaling assays in T-47D human mammary tumor cells; comparison with established antagonist G129R-hPRL\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with defined mutant; single lab moderate evidence\",\n      \"pmids\": [\"11517174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Human pituitary PRL is serine-phosphorylated at serine 194 and serine 163, whereas serine 163 is dephosphorylated in serum PRL; anti-PRL autoantibody IgG subclasses show IgG4 predominance consistent with chronic antigen stimulation, and acidic PRL isoforms in affected patients may trigger this chronic stimulation.\",\n      \"method\": \"Western blot, mass spectrometry, and two-dimensional electrophoresis of human pituitary and serum PRL; enzyme immunoassay for IgG subclasses\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mass spectrometry plus 2D electrophoresis identifying specific phosphorylation sites; single lab\",\n      \"pmids\": [\"15687336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A heterozygous stop-gain mutation in PRL exon 5 (p.Arg220Ter) results in normal intracellular prolactin accumulation but failure of prolactin secretion; loss of the terminal cysteine (which forms a disulfide bond with the penultimate cysteine) is critical for PRL protein secretion, and this secretion defect is not rescued by deleting both terminal cysteines.\",\n      \"method\": \"PRL gene sequencing of family members with alactogenesis; transfection of wild-type and mutant PRL constructs into cells; measurement of intracellular and secreted immunoactive and bioactive prolactin in conditioned medium\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional secretion assay; single family/lab but mechanistically informative\",\n      \"pmids\": [\"33770166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Human pituitary PRL binds zinc (Zn++) at a site involving histidine 27 (H27); Zn++ binding promotes self-association/aggregation of PRL monomers, and the H27A mutant has greatly reduced Zn++ binding but retains normal biological activity and folding, demonstrating that Zn++ binding and self-association are decoupled in PRL.\",\n      \"method\": \"Radiolabeled (65)Zn++ binding assay; Scatchard analysis; Nb2 cell bioassay; circular dichroism; dynamic light scattering; sedimentation equilibrium analysis of wild-type and H27A mutant hPRL\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assays with mutagenesis and biophysical characterization; single lab\",\n      \"pmids\": [\"8833655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Serotonin, acting through 5HT2 receptors, is involved in stimulating PRL release during insulin-induced hypoglycemia in humans, as ketanserin (a selective 5HT2 antagonist) reduced the PRL response to hypoglycemia by ~50%.\",\n      \"method\": \"Randomized crossover study in normal male subjects; ketanserin iv administration during insulin tolerance test; serial measurements of PRL, ACTH, cortisol, and GH\",\n      \"journal\": \"Clinical endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological receptor blockade in human subjects; single study\",\n      \"pmids\": [\"6325044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Ovine PRL and dopamine both inhibit PRL release from the same subpopulation of rat mammotropes but through separate intracellular mechanisms; chloroquine (a lysosomotropic agent) overrides dopamine inhibition but not oPRL inhibition, indicating distinct pathways converging on the same cells.\",\n      \"method\": \"Reverse hemolytic plaque assay at single-cell level; preincubation with oPRL, dopamine, TRH, chloroquine; quantification of plaque development rate as index of PRL secretion\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single-cell functional assay with pharmacological dissection; single lab\",\n      \"pmids\": [\"3093192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"In intact female rats, rat GH (but not rat or ovine PRL) induces upregulation of both GH and PRL receptors in liver; PRL infusion does not induce its own hepatic receptors and causes slight down-regulation of PRL binding, demonstrating that GH regulates PRL receptor concentration in liver.\",\n      \"method\": \"Osmotic minipump hormone infusion in intact female rats; radioligand binding assays for GH and PRL receptors on liver microsomal membranes; MgCl2 stripping of bound hormones; competitive binding curve analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo infusion with quantitative receptor binding analysis; single lab\",\n      \"pmids\": [\"6325135\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Prolactin (PRL) is a pituitary hormone whose secretion is tonically inhibited by dopamine acting via D2 receptors on lactotrophs (controlling calcium fluxes and intracellular signaling) and stimulated by serotonin (via 5HT2 receptors); upon binding its receptor (PRLR), PRL activates JAK2, which phosphorylates STAT5 to drive transcription of target genes including cyclin D1 and milk proteins, with the long PRLR isoform mediating JAK2/STAT5 signaling in mammary gland while the short isoform in liver does not activate this pathway; PRL is also required for normal pancreatic beta-cell development and insulin secretion in vivo; the hormone itself is regulated by serine phosphorylation, Zn++-mediated self-association, and anti-PRL autoantibody complex formation that slows clearance, and its secretion depends critically on an intact C-terminal disulfide bond.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI need to carefully classify each paper before extracting discoveries.\n\n**Classification:**\n\nThe gene query is PRL = **Prolactin** (the human pituitary hormone, HGNC:9445).\n\nHowever, a large portion of the corpus is about **PRL-1, PRL-2, PRL-3** = **Phosphatases of Regenerating Liver** (PTP4A1, PTP4A2, PTP4A3) — these are completely different genes/proteins. These must be EXCLUDED as alias collisions.\n\nAdditional exclusions:\n- Papers about *prl* genes in E. coli (protein secretion), Listeria, Metarhizium (fungal protease), Plasmodium — SYMBOL COLLISION\n- Papers about phakic refractive lens (PRL) — SYMBOL COLLISION  \n- Papers about PRL-295 (Keap1/Nrf2 compound) — SYMBOL COLLISION\n- Papers about PRL-2903 (somatostatin antagonist) — SYMBOL COLLISION\n- Papers about atanyl blue PRL (antiviral) — SYMBOL COLLISION\n- Papers about livestock/buffalo/sheep/goat/duck PRL polymorphisms — KEEP if about prolactin biology, but most are pure association/SNP studies → EXCLUDE (no mechanism)\n- BioPlex interactome papers — too generic, no specific PRL mechanistic finding → EXCLUDE\n\n**KEEP** (canonical prolactin hormone, PRL):\n- PMID:11739329 (dopamine as PRL inhibitor)\n- PMID:11897695 (PRLR knockout effects on islets)\n- PMID:11923474 (PRL activates cyclin D1 via Jak2/Stat5)\n- PMID:9284753 (anti-PRL autoantibodies, IgG complex, clearance)\n- PMID:6325135 (GH induces PRL receptors in rat liver)\n- PMID:1537321 (PRL-R mRNA in rat hypothalamus/pituitary)\n- PMID:9314595 (JAK/STAT pathway during lactogenesis in rat)\n- PMID:15687336 (PRL phosphorylation at serine 194/163)\n- PMID:3002768 (antiidiotypic antibodies recognize PRL receptor)\n- PMID:3093192 (ovine PRL and dopamine inhibit same subpopulation)\n- PMID:2464129 (discrepancy PRL mRNA vs content, dopamine role)\n- PMID:8721989 (chimeric PRL receptors, JAK/STAT convergence)\n- PMID:10687859 (MAPK activation by PRL, negative regulatory role of C-terminal PRLR)\n- PMID:8833655 (Zn++ binding, self-association of human PRL)\n- PMID:17289576 (cathepsin D cleaves 16 kDa PRL, PPCM)\n- PMID:23619365 (16K PRL induces miR-146a, PPCM mechanism)\n- PMID:7984244 (crystal structure GH-PRLR complex)\n- PMID:6260780 (human PRL cDNA structural analysis)\n- PMID:6325171 (isolation/characterization human PRL gene)\n- PMID:8015553 (nonpituitary PRL gene transcription, alternative promoter)\n- PMID:1697858 (alternative noncoding exon in decidua/lymphoblast)\n- PMID:9626554 (PRL and its receptor, signal transduction)\n- PMID:22577091 (molecular mechanisms of prolactin)\n- PMID:12679477 (PRL inhibits LPL activity in human adipose tissue)\n- PMID:16507890 (PRL in human hair follicles, catagen-promoting)\n- PMID:743954 (intracellular transport/packaging of prolactin)\n- PMID:7221563 (PRL gene on chromosome 6)\n- PMID:23530035 (ECM stiffness regulates PRL signals in breast cancer)\n- PMID:18254957 (PRL/Jak2/Stat5 signaling quantification)\n- PMID:33770166 (PRL mutation causing alactogenesis)\n- PMID:25472537 (plasticity of PRL axis, lactotroph network)\n- PMID:11517174 (S179D-human PRL agonist characterization)\n- PMID:9083259 (lactogenic hormones feedback, ante-partum PRL surge)\n- PMID:7534770 (laminin decreases PRL expression in decidualization)\n- PMID:6325044 (ketanserin/serotonin role in PRL response to hypoglycemia)\n- PMID:9284753 already listed\n- PMID:20609352 — this is about PRL-3 phosphatase → EXCLUDE\n- PMID:29378204 (glial cells as mediators of PRL protection in CNS) — mechanistic review → limited mechanism\n- PMID:31084703 (PVN-PrL OTergic pathway) — about OT not PRL hormone → EXCLUDE\n\nNow extracting mechanistic discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1981,\n      \"finding\": \"Human prolactin (PRL) cDNA was cloned and sequenced, revealing the complete coding sequence of pre-prolactin and establishing sequence homology with growth hormone, consistent with evolution from a common ancestral gene. The coding sequence predicts a signal peptide and mature hormone structure.\",\n      \"method\": \"cDNA cloning and nucleotide sequencing from pituitary prolactinoma mRNA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original sequence determination, foundational structural characterization\",\n      \"pmids\": [\"6260780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"The human prolactin gene was mapped to chromosome 6, distinct from the chromosomal locations of growth hormone and chorionic somatomammotropin genes, using somatic cell hybrid analysis.\",\n      \"method\": \"Somatic cell hybrid panel analysis with Southern blotting\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping with multiple hybrid lines\",\n      \"pmids\": [\"7221563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The human PRL gene was isolated, shown to be a single-copy gene of ~10 kb containing four introns, three of which interrupt the coding sequence at positions conserved with GH and PRL genes, and the transcription origin was determined by S1 mapping.\",\n      \"method\": \"Genomic library screening, restriction mapping, DNA sequencing, S1 nuclease mapping\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural characterization of genomic locus with multiple orthogonal methods\",\n      \"pmids\": [\"6325171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1978,\n      \"finding\": \"Prolactin is synthesized in the rough endoplasmic reticulum (ER) of mammotrophs, rapidly transported to the Golgi (within 5–10 min), and sequentially packaged into immature then mature secretory granules over ~3 hours, with progressive ~20–150-fold concentration along the transport route.\",\n      \"method\": \"Quantitative electron microscopic autoradiography using pulse-chase [3H]leucine labeling of dispersed rat pituitary cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative ultrastructural pulse-chase defining the complete intracellular transport pathway\",\n      \"pmids\": [\"743954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"In intact female rats, rat GH (but not prolactin itself) induces upregulation of both GH and PRL receptors in the liver in a dose-dependent manner. PRL infusion caused slight downregulation of PRL receptors rather than induction, challenging the concept that PRL auto-induces its own hepatic receptors.\",\n      \"method\": \"Osmotic minipump infusion of recombinant hormones followed by radioligand binding assay and MgCl2 stripping on liver microsomal membranes\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous in vivo dose-response with appropriate controls and multiple hormone comparisons\",\n      \"pmids\": [\"6325135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Ovine PRL and dopamine inhibit basal PRL release from the same subpopulation of rat mammotrophs, but by separate intracellular mechanisms: chloroquine (a lysosomotropic agent) reversed dopamine inhibition but not PRL-mediated inhibition, indicating distinct pathways converging on the same cells.\",\n      \"method\": \"Reverse hemolytic plaque assay on dispersed rat pituitary cells with pharmacological inhibitors\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — single-cell functional assay with pharmacological dissection of two inhibitory mechanisms\",\n      \"pmids\": [\"3093192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Antiidiotypic antibodies raised against anti-PRL antibodies specifically bind to PRL receptor-rich membrane preparations and competitively inhibit [125I]-PRL binding to its receptor, demonstrating that anti-PRL idiotypes share structural determinants with the PRL receptor binding site.\",\n      \"method\": \"Affinity chromatography purification of antibodies, [125I]-Protein A precipitation binding assay, competitive inhibition assays on tissue membrane preparations\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — indirect binding assay establishing structural mimicry between receptor and anti-hormone antibody idiotypes\",\n      \"pmids\": [\"3002768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"In rat fetal pituitary, PRL mRNA (detectable from fetal day 18) is present at levels disproportionately higher than PRL protein content, and dopamine promotes PRL storage post-birth; in vitro, newborn pituitary cells store PRL when cultured with dopamine, indicating dopamine regulates PRL accumulation/storage rather than synthesis at the neonatal stage.\",\n      \"method\": \"Immunocytochemistry, in situ hybridization, cDNA probe hybridization quantification, in vitro dopamine treatment of primary pituitary cells, radioimmunoassay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in one study, but single laboratory\",\n      \"pmids\": [\"2464129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Human PRL gene expression in extrapituitary sites (decidua and lymphoblasts) is initiated from an alternative promoter located ~6 kb upstream of the pituitary-specific start site, producing mRNA with a distinct 5'-noncoding exon; this extrapituitary transcript encodes the same mature PRL protein.\",\n      \"method\": \"cDNA cloning, 5'-UTR sequencing, S1 mapping, Northern blot analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequence determination and promoter mapping establishing alternative transcription start site\",\n      \"pmids\": [\"1697858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"PRL receptor (PRL-R) mRNA, including both long and short isoforms, is expressed in the rat anterior pituitary, medial basal hypothalamus, and posterior pituitary — in addition to peripheral tissues — as demonstrated by RT-PCR, indicating PRL can feed back on its own secretion through receptors at both hypothalamic and pituitary levels.\",\n      \"method\": \"Reverse transcription-PCR with isoform-specific primers on RNA from multiple brain and peripheral tissues\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific PCR with tissue panel; functional implication supported by known physiology but localization alone\",\n      \"pmids\": [\"1537321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The extrapituitary PRL promoter (decidual/lymphoid promoter) driving PRL gene expression in endometrial stroma and lymphocytes is independent of Pit-1 (the pituitary-specific transcription factor) and is not directly controlled by progesterone receptor, but is activated by cAMP signaling in endometrial stromal cells.\",\n      \"method\": \"Transfection of promoter-reporter constructs (3 kb 5'-flanking dPRL) into multiple cell types, Pit-1 co-expression experiments, pharmacological cAMP stimulation\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell lines, promoter deletion/mutation analysis, pharmacological approach; Pit-1 independence confirmed by overexpression\",\n      \"pmids\": [\"8015553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The crystal structure of hGH bound to the extracellular domain of the human PRL receptor (hPRLR) at 1:1 stoichiometry was solved, revealing the structural basis for how hGH binds to two distinct receptor types (hGHR and hPRLR) through overlapping but non-identical receptor-binding surfaces.\",\n      \"method\": \"X-ray crystallography of hGH–hPRLR extracellular domain complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with direct structural insight into receptor binding specificity\",\n      \"pmids\": [\"7984244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Human PRL binds Zn²⁺ at a site involving histidine-27 (H27); the H27A mutant shows greatly reduced Zn²⁺ binding but retains normal biological activity and fold, demonstrating that Zn²⁺ binding to the high-affinity site is not required for receptor activation but promotes concentration-dependent self-association/aggregation of PRL.\",\n      \"method\": \"65Zn binding assays, Scatchard analysis, Nb2 cell bioassay, circular dichroism spectroscopy, dynamic light scattering, sedimentation equilibrium analysis\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis combined with multiple biophysical assays and functional validation\",\n      \"pmids\": [\"8833655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Chimeric PRL receptors bearing the transmembrane/cytoplasmic domains of IL-2Rβ or βc cytokine receptor subunits transduce PRL signals through Jak1 and Jak2 respectively, both leading to Stat5 tyrosine phosphorylation, DNA binding, and β-casein promoter activation, demonstrating that distinct cytoplasmic domains converge on the same Stat5-dependent transcriptional output and that Stat5 activation is not dependent on a specific JAK kinase.\",\n      \"method\": \"Stably transfected CHO cells expressing chimeric receptors, Western blotting for phospho-Jak1/Jak2/Stat5, EMSA with LHRR probe, luciferase reporter assay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chimeric receptor approach with multiple orthogonal readouts in stable cell lines\",\n      \"pmids\": [\"8721989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"During in vivo lactogenesis in rats, PRL activates JAK2 and STAT5 in mammary gland (but not in liver) despite the PRL receptor being constitutively associated with JAK2 in both tissues. The long-form PRL-R predominates in mammary gland, while the short form is abundant in liver and may form inactive heterodimers with the long form, explaining tissue-specific signal activation.\",\n      \"method\": \"In vivo PRL injection in ovario-hysterectomized rats, immunoprecipitation/Western blot for phospho-JAK2 and phospho-PRLR, EMSA for STAT5 binding using β-casein probe, quantitative RT-PCR for receptor isoforms\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with reciprocal Co-IP and EMSA, tissue-specific comparison with quantitative isoform analysis\",\n      \"pmids\": [\"9314595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Anti-PRL IgG autoantibodies form non-covalent complexes with 23 kDa monomeric PRL (which retains full bioactivity in vitro), and the IgG-PRL complex is cleared more slowly from rat circulation than free PRL, explaining macroprolactinemia as a result of delayed metabolic clearance rather than increased secretion.\",\n      \"method\": \"Enzyme immunoassay, Nb2-cell bioassay, gel chromatography, affinity chromatography, SDS-PAGE under non-reducing conditions, pharmacokinetic clearance studies in anesthetized rats\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods plus in vivo clearance studies, establishing mechanism of macroprolactinemia\",\n      \"pmids\": [\"9284753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PRL receptor (PRLR) knockout mice display: infertility in homozygous females (due to ovulation of premeiotic oocytes, reduced fertilization, lack of implantation), near-complete failure to lactate in heterozygous females after first pregnancy, and reduced islet/beta-cell function, establishing the physiological roles of PRL/lactogen signaling through the PRLR in reproductive function and lactation.\",\n      \"method\": \"Targeted gene deletion in mice (PRLR knockout), phenotypic analysis of reproductive outcomes, histology, hormone assays\",\n      \"journal\": \"Endocrine reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function genetic model with multiple defined phenotypic readouts; foundational review summarizing original KO studies\",\n      \"pmids\": [\"9626554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The C-terminal cytoplasmic domain of the PRL receptor exerts a negative regulatory role on PRL-induced MAPK (ERK) activation; MAPK activation by PRL requires both MEK-dependent and PI3K-dependent pathways, and the negative regulation by the C-terminal domain involves tyrosine phosphatases and serine/threonine phosphatases recruited by the last 141 residues.\",\n      \"method\": \"Transient transfection of PRL-R cytoplasmic domain deletion/truncation mutants in CHO cells, pharmacological inhibitors (pervanadate, PAO, okadaic acid, MEK inhibitor, PI3K inhibitor), Western blot for phospho-ERK\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic receptor mutant analysis with pharmacological dissection; single laboratory\",\n      \"pmids\": [\"10687859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dopamine suppresses PRL secretion from pituitary lactotrophs by binding D2 dopamine receptors coupled to membrane ion channels and G proteins, controlling calcium fluxes and activating intracellular signaling pathways, while also suppressing PRL gene expression and lactotroph proliferation. PRL homeostasis is determined by this inhibitory dopamine tone balanced against multiple stimulatory factors.\",\n      \"method\": \"Review integrating pharmacological, transgenic animal, and clinical studies; calcium flux measurements, receptor characterization, gene expression assays\",\n      \"journal\": \"Endocrine reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic review of extensively replicated findings across multiple labs and model systems\",\n      \"pmids\": [\"11739329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"S179D-human PRL (designed to mimic phospho-S179 PRL) acts as an agonist, not an antagonist, at the human PRL receptor: it stimulates Nb2 cell proliferation, T-47D cell proliferation, transcriptional activation of lactogenic response element reporters, and activates JAK/STAT and MAPK pathways, albeit with slightly reduced affinity due to local alteration of receptor binding site 1.\",\n      \"method\": \"Nb2 lymphoma cell proliferation bioassay, T-47D human mammary tumor cell proliferation assay, lactogenic hormone response element-luciferase reporter assay, Western blot for JAK2/STAT5/MAPK phosphorylation\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays and signaling readouts; directly refutes prior claims of antagonism\",\n      \"pmids\": [\"11517174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PRL-receptor-deficient (PRLR KO) mice exhibit 26–42% reductions in islet density and beta-cell mass from as early as 3 weeks of age, with reduced pancreatic insulin mRNA, lower islet insulin content, blunted glucose-stimulated insulin secretion both in vivo and in vitro, and impaired glucose tolerance, establishing a physiological role for lactogenic hormones in islet development and beta-cell function.\",\n      \"method\": \"PRLR knockout mouse model, morphometric analysis of islet density and beta-cell mass, pancreatic insulin mRNA quantification, static and dynamic glucose-stimulated insulin secretion assays, intraperitoneal glucose tolerance test\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function model with multiple quantitative phenotypic readouts across sexes and ages\",\n      \"pmids\": [\"11897695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PRL significantly increases proliferation of mammary carcinoma cells and upregulates cyclin D1 mRNA/protein levels via transcriptional activation of the cyclin D1 promoter through the JAK2/STAT5 pathway. PRL-induced Stat5a and Stat5b bind as a heterodimer to a distal GAS site in the cyclin D1 promoter; disruption of this distal GAS site abolishes PRL-induced promoter activity.\",\n      \"method\": \"Cell proliferation assays, cyclin D1 protein immunoblot, actinomycin D transcription block, cyclin D1 promoter-luciferase reporter assay in CHO cells, EMSA demonstrating STAT5 binding to GAS sites, co-immunoprecipitation of STAT5a/5b heterodimers from nuclear extracts\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (reporter assay, EMSA, Co-IP) with specific promoter element identification\",\n      \"pmids\": [\"11923474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PRL directly inhibits lipoprotein lipase (LPL) activity in human white adipose tissue to ~31% of control via functional PRL receptors (long and intermediate isoforms expressed in adipose tissue), demonstrating a direct metabolic action of PRL on lipid metabolism in humans.\",\n      \"method\": \"RT-PCR/Southern blot and immunoblot for PRLR isoforms in human adipose tissue, in vitro culture of human adipose tissue with PRL/GH/cortisol, LPL enzyme activity assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor expression confirmed plus functional enzymatic assay in primary human tissue\",\n      \"pmids\": [\"12679477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human pituitary PRL is phosphorylated at serine 194 and serine 163; serine 163 is dephosphorylated in serum PRL. Acidic PRL isoforms (with distinct pI) are enriched in macroprolactinemic patients with anti-PRL autoantibodies and may contribute to chronic antigen stimulation (IgG4-predominant response).\",\n      \"method\": \"Western blot, mass spectrometry, two-dimensional electrophoresis, enzyme immunoassay for IgG subclasses\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry identification of phosphorylation sites on human PRL with biochemical validation\",\n      \"pmids\": [\"15687336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human scalp hair follicles express both PRL and PRL receptors at mRNA and protein level, and treatment of organ-cultured human hair follicles with high-dose PRL (400 ng/ml) inhibits hair shaft elongation, promotes premature catagen development, reduces keratinocyte proliferation, and increases apoptosis, demonstrating PRL acts as an autocrine/paracrine catagen-promoting factor in human skin.\",\n      \"method\": \"RT-PCR, immunohistology for PRL and PRL-R, organ culture of human scalp hair follicles with PRL, Ki-67/TUNEL immunohistomorphometry\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional organ culture with quantitative cellular readouts; both receptor expression and functional response demonstrated\",\n      \"pmids\": [\"16507890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In mice with cardiomyocyte-specific STAT3 deletion, enhanced cardiac cathepsin D (CD) activity cleaves full-length prolactin into an antiangiogenic/proapoptotic 16 kDa N-terminal fragment that impairs cardiac capillary network and function, causing postpartum cardiomyopathy (PPCM). Bromocriptine (prolactin secretion inhibitor) prevents PPCM, and forced cardiac generation of 16 kDa PRL recapitulates the PPCM phenotype.\",\n      \"method\": \"Cardiomyocyte-specific Stat3 knockout mice, cathepsin D activity assay, Western blot for 16 kDa PRL fragment, bromocriptine treatment, forced myocardial 16 kDa PRL overexpression, cardiac function/capillary network assessment, measurement of serum CD and 16 kDa PRL in human PPCM patients\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic reconstitution (forced 16 kDa PRL expression recapitulates phenotype), genetic model, and pharmacological intervention; multiple orthogonal approaches validated in human samples\",\n      \"pmids\": [\"17289576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The PRL/JAK2/STAT5 signaling pathway is enhanced in estrogen receptor-positive (ER+) breast cancer cells (T47D, MCF7) compared with ER-negative lines, as measured by a highly sensitive pGL4-CISH luciferase reporter; overexpression of STAT5 further amplifies PRL-driven CISH reporter activation.\",\n      \"method\": \"Luciferase reporter assay (pGL4-CISH) in multiple cell lines, STAT5 overexpression, comparison across ER+ and ER- cell lines\",\n      \"journal\": \"BMC biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — reporter assay establishing ER-status-dependent PRL/STAT5 signaling differences; single method\",\n      \"pmids\": [\"18254957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Prolactin receptor activation and signaling involve: (1) sequential two-step binding where site 1 on PRL binds one receptor molecule, then site 2 binds a second receptor to form a 1:2 (PRL:PRLR) homodimer; (2) receptor dimerization activates associated JAK2 kinase (no intrinsic kinase domain in PRLR), leading to phosphorylation of JAK2 and the receptor; (3) downstream activation of STAT5, Ras/Raf/MAPK, IRS-1/PI3K, SHP-2, PLCγ, and PKC pathways. Three human hormones (PRL, GH, placental lactogen) can activate the PRLR through structurally distinct mechanisms.\",\n      \"method\": \"Comprehensive mechanistic review integrating structural, biochemical, and genetic studies\",\n      \"journal\": \"Endocrine reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — synthesis of crystallographic, mutagenesis, and biochemical data establishing the canonical receptor activation mechanism\",\n      \"pmids\": [\"22577091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The 16 kDa N-terminal PRL fragment induces microRNA-146a (miR-146a) expression in endothelial cells (ECs), which attenuates angiogenesis by downregulating NRAS. 16K PRL stimulates secretion of miR-146a-loaded exosomes from ECs; these exosomes are absorbed by cardiomyocytes, raising miR-146a levels and decreasing metabolic activity and expression of Erbb4, Notch1, and Irak1, thereby contributing to PPCM pathogenesis.\",\n      \"method\": \"miRNA expression profiling, luciferase reporter for NRAS 3'UTR, exosome isolation and transfer experiments, cardiomyocyte-specific Stat3 KO mouse model, locked nucleic acid/antago-miR treatment, measurement of miR-146a in PPCM patient plasma and hearts\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway from 16K PRL to miR-146a to cardiomyocyte dysfunction, validated in mouse model and human samples with functional rescue\",\n      \"pmids\": [\"23619365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Stiff collagen matrices shift prolactin signaling in luminal breast cancer cells from STAT5-mediated physiological outcomes to SRC family kinase-dependent FAK phosphorylation (pY925), FAK-GRB2 association, and ERK1/2 activation, promoting matrix metalloproteinase-dependent invasion. Co-localization of PRL receptors with integrin-activated FAK increases in stiff matrices, implicating altered spatial receptor organization.\",\n      \"method\": \"Three-dimensional collagen I matrix culture with defined stiffness, Western blot for phospho-STAT5/FAK/ERK, matrix metalloproteinase invasion assay, pharmacological SRC inhibitors, immunofluorescence co-localization of PRLR and FAK\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — controlled ECM stiffness system with multiple signaling readouts and pharmacological validation; single laboratory\",\n      \"pmids\": [\"23530035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A heterozygous stop-gain mutation in PRL exon 5 (p.Arg220Ter, c.658C>T) causes familial prolactin deficiency and alactogenesis. Transfection of the mutant PRL produces normal intracellular prolactin levels but fails to secrete immunoactive or bioactive prolactin; deletion of the terminal cysteine (p.Lys218Ter) also impairs secretion and cannot be rescued by removing the penultimate cysteine, indicating the C-terminal disulfide bond is essential for PRL secretion.\",\n      \"method\": \"Sanger sequencing of PRL exons, transfection of wild-type and mutant PRL constructs, conditioned medium immunoassay for secreted PRL, Nb2-cell bioassay for bioactive PRL\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional mutagenesis in transfected cells with paired secretion and bioactivity assays, validated in familial human mutation\",\n      \"pmids\": [\"33770166\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Prolactin (PRL) is a single-copy pituitary hormone (chromosome 6) that is synthesized in the ER of lactotrophs, packaged via Golgi into secretory granules, and secreted under tonic inhibition by dopamine acting through D2 receptors/calcium flux; its secretion requires intact C-terminal disulfide bonds. PRL binds its receptor (PRLR) through a sequential two-step mechanism forming a 1:2 ligand-receptor homodimer that activates constitutively associated JAK2, leading to receptor and JAK2 phosphorylation, STAT5 dimerization and nuclear translocation (driving target genes such as cyclin D1 and β-casein), and parallel activation of Ras/MAPK and PI3K pathways; the C-terminal cytoplasmic domain of the PRLR exerts negative feedback on MAPK activation via phosphatase recruitment. Extrapituitary PRL expression uses an alternative upstream promoter activated by cAMP independently of Pit-1. Pituitary PRL is phosphorylated at Ser-163/Ser-194, and cathepsin D can cleave full-length PRL into an antiangiogenic 16 kDa fragment that drives postpartum cardiomyopathy via exosomal miR-146a transfer to cardiomyocytes. PRL also directly inhibits lipoprotein lipase in adipose tissue, promotes catagen in hair follicles, and is required (via lactogenic signaling through the PRLR) for normal beta-cell mass and islet development.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"Prolactin (PRL) is a pituitary peptide hormone that signals through the JAK2–STAT5 axis to regulate mammary gland differentiation, lactation, and pancreatic beta-cell development, while its secretion is tonically inhibited by dopamine via D2 receptors and stimulated by serotonin via 5-HT2 receptors. PRL binding to the long isoform of the PRL receptor (PRLR) in mammary gland activates JAK2, leading to STAT5a/5b phosphorylation, nuclear translocation, and transcription of target genes including cyclin D1 and beta-casein, whereas the short PRLR isoform predominant in liver does not activate this pathway; PRL also engages MAPK through MEK- and PI3K-dependent routes, with the PRLR C-terminal domain exerting negative regulation via phosphatases [PMID:9314595, PMID:11923474, PMID:10687859]. Lactogenic signaling through PRLR is required for normal islet development, beta-cell mass, and glucose-stimulated insulin secretion, as demonstrated in PRLR-knockout mice [PMID:11897695]. PRL itself is regulated post-translationally by serine phosphorylation at Ser163 and Ser194, Zn²⁺-mediated self-association via His27, and an essential C-terminal disulfide bond whose disruption abolishes secretion and causes alactogenesis [PMID:15687336, PMID:8833655, PMID:33770166].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Establishing that serotonin stimulates PRL release through 5-HT2 receptors answered how hypothalamic serotonergic input positively regulates lactotroph secretion in humans.\",\n      \"evidence\": \"Randomized crossover study in normal males using ketanserin (selective 5-HT2 antagonist) during insulin-induced hypoglycemia, showing ~50% reduction in PRL response\",\n      \"pmids\": [\"6325044\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single pharmacological study without genetic confirmation of receptor subtype\",\n        \"Mechanism by which 5-HT2 activation drives PRL exocytosis not resolved\",\n        \"Interaction between serotonergic stimulation and dopaminergic inhibition at the cellular level unknown\"\n      ]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Demonstrating that GH — not PRL itself — upregulates hepatic PRL receptors clarified how liver PRLR expression is regulated and why PRL does not auto-amplify its own hepatic signaling.\",\n      \"evidence\": \"Osmotic minipump infusion of GH or PRL in intact female rats with radioligand binding assays on liver microsomes\",\n      \"pmids\": [\"6325135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular mechanism of GH-driven PRLR upregulation not identified\",\n        \"Applicability to human liver not tested\"\n      ]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Single-cell analysis revealed that PRL and dopamine both inhibit PRL release from the same mammotrope subpopulation but through separable intracellular mechanisms, establishing the concept of convergent but independent inhibitory control.\",\n      \"evidence\": \"Reverse hemolytic plaque assay on individual rat mammotropes with pharmacological dissection using chloroquine, dopamine, and ovine PRL\",\n      \"pmids\": [\"3093192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular identities of the distinct intracellular pathways not resolved\",\n        \"Whether short-loop PRL feedback operates through PRLR on lactotrophs not confirmed\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of His27 as the Zn²⁺-binding site mediating PRL self-association, with retention of bioactivity in the H27A mutant, decoupled zinc-induced aggregation from receptor activation and defined a distinct structural feature of PRL.\",\n      \"evidence\": \"⁶⁵Zn²⁺ binding, Scatchard analysis, Nb2 bioassay, CD, DLS, and sedimentation equilibrium on wild-type and H27A human PRL\",\n      \"pmids\": [\"8833655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological role of Zn²⁺-induced PRL aggregation in storage granules or serum unclear\",\n        \"No structural model at atomic resolution for the Zn²⁺ binding site\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Chimeric PRLR experiments showed that diverse cytokine receptor cytoplasmic domains all converge on JAK–STAT5 activation and beta-casein transcription, establishing STAT5 as the central transcriptional effector downstream of PRLR.\",\n      \"evidence\": \"CHO cells expressing chimeric PRL receptor–IL-2Rβ or –βc constructs; kinase assays, EMSA, and beta-casein promoter-luciferase reporters\",\n      \"pmids\": [\"8721989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Relative contributions of JAK1 vs JAK2 to endogenous PRLR signaling not distinguished\",\n        \"In vivo relevance of chimeric receptor findings not tested\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mass spectrometry identified Ser194 and Ser163 as phosphorylation sites on pituitary PRL, with Ser163 dephosphorylated in circulating PRL, revealing post-translational regulation of the hormone itself.\",\n      \"evidence\": \"Mass spectrometry and 2D electrophoresis of human pituitary and serum PRL; IgG subclass analysis of anti-PRL autoantibodies\",\n      \"pmids\": [\"15687336\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Kinase(s) responsible for Ser163/Ser194 phosphorylation not identified\",\n        \"Functional consequence of Ser163 dephosphorylation on receptor binding or bioactivity not established\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"In vivo demonstration that PRL activates JAK2–STAT5 in mammary gland but not liver resolved the tissue-specificity question and linked it to differential expression of long vs. short PRLR isoforms.\",\n      \"evidence\": \"Rat lactogenesis model with immunoprecipitation, phospho-Western blot, EMSA with beta-casein STAT5 probe, and RT-PCR for PRLR isoforms\",\n      \"pmids\": [\"9314595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for why the short PRLR isoform cannot activate STAT5 not fully resolved\",\n        \"Whether short-form PRLR has independent signaling functions not addressed\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Characterization of PRL–IgG complexes showed that anti-PRL autoantibodies preserve PRL bioactivity but slow clearance, explaining asymptomatic hyperprolactinemia ('macroprolactinemia').\",\n      \"evidence\": \"Gel chromatography, IgG affinity chromatography, Nb2 bioassay, and in vivo clearance studies in anesthetized rats\",\n      \"pmids\": [\"9284753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Epitope on PRL recognized by autoantibodies not mapped\",\n        \"Mechanism by which IgG complexation slows renal clearance not detailed\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping the PRLR domains required for MAPK activation showed that a membrane-proximal region is necessary and the C-terminal region is inhibitory via phosphatases, establishing a second major signaling arm beyond JAK–STAT5.\",\n      \"evidence\": \"PRLR cytoplasmic-domain deletion constructs with MEK, PI3K, and phosphatase inhibitors; MAPK activation assays\",\n      \"pmids\": [\"10687859\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the adaptor linking PRLR membrane-proximal domain to Ras–MAPK not determined\",\n        \"Relative contribution of MAPK vs STAT5 to specific PRL-driven biological outcomes not quantified\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Comprehensive review consolidated that dopamine tonically inhibits PRL secretion, gene expression, and lactotroph proliferation via D2 receptors, establishing the primary neuroendocrine brake on PRL.\",\n      \"evidence\": \"Synthesis of pharmacological, transgenic, and receptor-binding studies across multiple labs\",\n      \"pmids\": [\"11739329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contributions of D2S vs D2L isoforms to each inhibitory arm remain debated\",\n        \"How D2 receptor-mediated signals couple to inhibition of lactotroph proliferation at molecular level incompletely defined\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of the distal GAS site on the cyclin D1 promoter as the STAT5a/5b heterodimer target linked PRL–STAT5 signaling directly to cell cycle control, providing a molecular mechanism for PRL-driven proliferation.\",\n      \"evidence\": \"Cyclin D1 promoter-luciferase reporters in CHO cells, EMSA with GAS probes, and nuclear co-IP of STAT5a/5b\",\n      \"pmids\": [\"11923474\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether STAT5 heterodimer vs homodimer binding drives different transcriptional outcomes not tested\",\n        \"Chromatin-level regulation (histone modifications) at the cyclin D1 locus not examined\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"PRLR-knockout mice revealed that lactogenic signaling through PRLR is essential for normal pancreatic islet development, beta-cell mass, and insulin secretion, extending PRL function beyond lactation to metabolic homeostasis.\",\n      \"evidence\": \"PRLR-null mice with measurements of islet density, beta-cell mass, insulin mRNA, islet insulin content, and glucose tolerance tests\",\n      \"pmids\": [\"11897695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PRL or placental lactogen is the primary ligand for islet PRLR in vivo not distinguished\",\n        \"Downstream transcriptional targets of PRLR in beta cells not identified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A human stop-gain mutation (p.Arg220Ter) causing loss of the C-terminal disulfide bond demonstrated that this bond is essential for PRL secretion but not intracellular accumulation, linking PRL structural integrity to a Mendelian alactogenesis phenotype.\",\n      \"evidence\": \"Family sequencing identifying the PRL mutation; transfection of wild-type and mutant constructs with measurement of intracellular vs secreted PRL\",\n      \"pmids\": [\"33770166\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single family; independent replication in additional kindreds not yet reported\",\n        \"Whether secretion failure reflects misfolding-driven ER retention not mechanistically resolved\",\n        \"Rescue experiments with disulfide-restoring mutations not performed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the kinase(s) phosphorylating PRL at Ser163/Ser194, the physiological role of Zn²⁺-mediated PRL aggregation, the structural basis for short PRLR isoform signaling incompetence, and the identity of direct PRL–STAT5 target genes in pancreatic beta cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Kinase responsible for PRL serine phosphorylation not identified\",\n        \"Full transcriptome of PRL-responsive genes in beta cells not mapped\",\n        \"No high-resolution structure of PRL–PRLR–JAK2 signaling complex\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0048018\",\n        \"supporting_discovery_ids\": [1, 2, 3, 7]\n      }\n    ],\n    \"localization\": [\n      {\n        \"term_id\": \"GO:0005576\",\n        \"supporting_discovery_ids\": [5, 9, 11]\n      }\n    ],\n    \"pathway\": [\n      {\n        \"term_id\": \"GO:0009314595\",\n        \"supporting_discovery_ids\": []\n      },\n      {\n        \"term_id\": \"R-HSA-162582\",\n        \"supporting_discovery_ids\": [1, 2, 4, 6, 7]\n      },\n      {\n        \"term_id\": \"R-HSA-1266738\",\n        \"supporting_discovery_ids\": [3]\n      },\n      {\n        \"term_id\": \"R-HSA-392499\",\n        \"supporting_discovery_ids\": [8, 10]\n      }\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PRLR\",\n      \"JAK2\",\n      \"STAT5A\",\n      \"STAT5B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I made an error in the pathway section — I included a bogus term_id. Let me fix that:\n\n```json\n{\n  \"mechanistic_narrative\": \"Prolactin (PRL) is a pituitary peptide hormone that signals through the JAK2–STAT5 axis to regulate mammary gland differentiation, lactation, and pancreatic beta-cell development, while its secretion is tonically inhibited by dopamine via D2 receptors and stimulated by serotonin via 5-HT2 receptors. PRL binding to the long isoform of the PRL receptor (PRLR) in mammary gland activates JAK2, leading to STAT5a/5b phosphorylation, nuclear translocation, and transcription of target genes including cyclin D1 and beta-casein, whereas the short PRLR isoform predominant in liver does not activate this pathway; PRL also engages MAPK through MEK- and PI3K-dependent routes, with the PRLR C-terminal domain exerting negative regulation via phosphatases [PMID:9314595, PMID:11923474, PMID:10687859]. Lactogenic signaling through PRLR is required for normal islet development, beta-cell mass, and glucose-stimulated insulin secretion, as demonstrated in PRLR-knockout mice [PMID:11897695]. PRL itself is regulated post-translationally by serine phosphorylation at Ser163 and Ser194, Zn²⁺-mediated self-association via His27, and an essential C-terminal disulfide bond whose disruption abolishes secretion and causes familial alactogenesis [PMID:15687336, PMID:8833655, PMID:33770166].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Establishing that serotonin stimulates PRL release through 5-HT2 receptors answered how hypothalamic serotonergic input positively regulates lactotroph secretion in humans.\",\n      \"evidence\": \"Randomized crossover study in normal males using ketanserin (selective 5-HT2 antagonist) during insulin-induced hypoglycemia, showing ~50% reduction in PRL response\",\n      \"pmids\": [\"6325044\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single pharmacological study without genetic confirmation of receptor subtype\",\n        \"Mechanism by which 5-HT2 activation drives PRL exocytosis not resolved\",\n        \"Interaction between serotonergic stimulation and dopaminergic inhibition at the cellular level unknown\"\n      ]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Demonstrating that GH — not PRL itself — upregulates hepatic PRL receptors clarified how liver PRLR expression is regulated and why PRL does not auto-amplify its own hepatic signaling.\",\n      \"evidence\": \"Osmotic minipump infusion of GH or PRL in intact female rats with radioligand binding assays on liver microsomes\",\n      \"pmids\": [\"6325135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular mechanism of GH-driven PRLR upregulation not identified\",\n        \"Applicability to human liver not tested\"\n      ]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Single-cell analysis revealed that PRL and dopamine both inhibit PRL release from the same mammotrope subpopulation but through separable intracellular mechanisms, establishing convergent but independent inhibitory control of lactotroph secretion.\",\n      \"evidence\": \"Reverse hemolytic plaque assay on individual rat mammotropes with pharmacological dissection using chloroquine, dopamine, and ovine PRL\",\n      \"pmids\": [\"3093192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular identities of the distinct intracellular pathways not resolved\",\n        \"Whether short-loop PRL feedback operates through PRLR on lactotrophs not confirmed\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of His27 as the Zn²⁺-binding site mediating PRL self-association, and serine phosphorylation at Ser163/Ser194, defined key post-translational modifications of the hormone itself.\",\n      \"evidence\": \"⁶⁵Zn²⁺ binding with H27A mutagenesis, Nb2 bioassay, biophysical characterization; mass spectrometry and 2D electrophoresis of pituitary and serum PRL\",\n      \"pmids\": [\"8833655\", \"15687336\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Kinase(s) responsible for Ser163/Ser194 phosphorylation not identified\",\n        \"Physiological role of Zn²⁺-induced PRL aggregation in secretory granules unclear\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Chimeric PRLR experiments showed that diverse cytokine receptor cytoplasmic domains converge on JAK–STAT5 activation and beta-casein transcription, establishing STAT5 as the central downstream transcription factor.\",\n      \"evidence\": \"CHO cells expressing chimeric PRL receptor–IL-2Rβ or –βc constructs; kinase assays, EMSA, and beta-casein promoter-luciferase reporters\",\n      \"pmids\": [\"8721989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Relative contributions of JAK1 vs JAK2 to endogenous PRLR signaling not distinguished\",\n        \"In vivo relevance of chimeric receptor findings not tested\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"In vivo demonstration that PRL activates JAK2–STAT5 in mammary gland but not liver resolved the tissue-specificity question and linked it to differential expression of long vs. short PRLR isoforms.\",\n      \"evidence\": \"Rat lactogenesis model with immunoprecipitation, phospho-Western blot, EMSA with beta-casein STAT5 probe, and RT-PCR for PRLR isoforms\",\n      \"pmids\": [\"9314595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for why the short PRLR isoform cannot activate STAT5 not fully resolved\",\n        \"Whether short-form PRLR has independent signaling functions not addressed\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Characterization of PRL–IgG complexes showed that anti-PRL autoantibodies preserve PRL bioactivity but slow clearance, explaining asymptomatic hyperprolactinemia (macroprolactinemia).\",\n      \"evidence\": \"Gel chromatography, IgG affinity chromatography, Nb2 bioassay, and in vivo clearance studies in anesthetized rats\",\n      \"pmids\": [\"9284753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Epitope on PRL recognized by autoantibodies not mapped\",\n        \"Mechanism by which IgG complexation slows renal clearance not detailed\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping the PRLR domains required for MAPK activation showed that a membrane-proximal region is necessary and the C-terminal region is inhibitory via phosphatases, establishing a second major signaling arm beyond JAK–STAT5.\",\n      \"evidence\": \"PRLR cytoplasmic-domain deletion constructs with MEK, PI3K, and phosphatase inhibitors; MAPK activation assays\",\n      \"pmids\": [\"10687859\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the adaptor linking PRLR membrane-proximal domain to Ras–MAPK not determined\",\n        \"Relative contribution of MAPK vs STAT5 to specific PRL-driven biological outcomes not quantified\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Comprehensive review consolidated that dopamine tonically inhibits PRL secretion, gene expression, and lactotroph proliferation via D2 receptors, and S179D-PRL was shown to retain agonist activity, refining models of phospho-PRL function.\",\n      \"evidence\": \"Review synthesizing pharmacological, transgenic, and receptor-binding studies; Nb2 bioassay, LHRRE-luciferase, JAK/STAT and MAPK assays for S179D-PRL\",\n      \"pmids\": [\"11739329\", \"11517174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contributions of D2S vs D2L isoforms to each inhibitory arm remain debated\",\n        \"Whether phospho-PRL has distinct physiological roles from unmodified PRL in vivo unknown\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of the cyclin D1 GAS site as a STAT5a/5b heterodimer target linked PRL signaling directly to cell cycle control, and PRLR-knockout mice extended PRL function to pancreatic islet development and insulin secretion.\",\n      \"evidence\": \"Cyclin D1 promoter-luciferase reporters with GAS mutagenesis, nuclear co-IP of STAT5a/5b; PRLR-null mice with islet phenotyping and glucose tolerance tests\",\n      \"pmids\": [\"11923474\", \"11897695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether STAT5 heterodimer vs homodimer binding drives different transcriptional outcomes not tested\",\n        \"Downstream transcriptional targets of PRLR signaling in beta cells not identified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A human stop-gain mutation (p.Arg220Ter) demonstrated that the C-terminal disulfide bond is essential for PRL secretion, linking PRL structural integrity to a Mendelian alactogenesis phenotype.\",\n      \"evidence\": \"Family sequencing; transfection of wild-type and mutant PRL constructs with measurement of intracellular vs secreted PRL\",\n      \"pmids\": [\"33770166\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single family; independent replication in additional kindreds not yet reported\",\n        \"Whether secretion failure reflects misfolding-driven ER retention not mechanistically resolved\",\n        \"Rescue experiments with disulfide-restoring mutations not performed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the kinase(s) phosphorylating PRL at Ser163/Ser194, the physiological role of Zn²⁺-mediated PRL aggregation, the structural basis for short PRLR isoform signaling incompetence, and the identity of direct PRL–STAT5 target genes in pancreatic beta cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Kinase responsible for PRL serine phosphorylation not identified\",\n        \"Full transcriptome of PRL-responsive genes in beta cells not mapped\",\n        \"No high-resolution structure of PRL–PRLR–JAK2 signaling complex\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0048018\",\n        \"supporting_discovery_ids\": [1, 2, 3, 7]\n      }\n    ],\n    \"localization\": [\n      {\n        \"term_id\": \"GO:0005576\",\n        \"supporting_discovery_ids\": [5, 9, 11]\n      }\n    ],\n    \"pathway\": [\n      {\n        \"term_id\": \"R-HSA-162582\",\n        \"supporting_discovery_ids\": [1, 2, 4, 6, 7]\n      },\n      {\n        \"term_id\": \"R-HSA-1266738\",\n        \"supporting_discovery_ids\": [3]\n      },\n      {\n        \"term_id\": \"R-HSA-392499\",\n        \"supporting_discovery_ids\": [8, 10]\n      }\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PRLR\",\n      \"JAK2\",\n      \"STAT5A\",\n      \"STAT5B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Prolactin (PRL) is a pituitary-derived peptide hormone that orchestrates lactation, reproductive function, metabolic homeostasis, and tissue remodeling through activation of the JAK2–STAT5 signaling axis and parallel MAPK and PI3K pathways. PRL is synthesized in the rough ER of lactotrophs, trafficked through the Golgi into secretory granules under tonic inhibitory control by dopamine acting via D2 receptors [PMID:743954, PMID:11739329]; its secretion requires an intact C-terminal disulfide bond, as demonstrated by a human loss-of-function mutation (p.Arg220Ter) causing familial prolactin deficiency and alactogenesis [PMID:33770166]. PRL binds the PRL receptor in a sequential 1:2 stoichiometry that activates constitutively associated JAK2, driving STAT5a/5b-dependent transcription of targets including cyclin D1 and β-casein, while the receptor's C-terminal cytoplasmic domain recruits phosphatases that negatively regulate MAPK output [PMID:22577091, PMID:11923474, PMID:10687859]. Extrapituitary PRL expression from a Pit-1-independent upstream promoter activated by cAMP enables autocrine/paracrine functions in decidua, lymphocytes, and hair follicles, and cathepsin D cleavage of full-length PRL generates a 16 kDa antiangiogenic fragment that drives peripartum cardiomyopathy through exosomal miR-146a transfer to cardiomyocytes [PMID:8015553, PMID:17289576, PMID:23619365].\",\n  \"teleology\": [\n    {\n      \"year\": 1978,\n      \"claim\": \"Defining the intracellular biosynthetic route of PRL—from ER synthesis through Golgi packaging to mature secretory granules—established the timeline and concentration steps underlying regulated hormone secretion from lactotrophs.\",\n      \"evidence\": \"Quantitative EM autoradiography with pulse-chase [³H]leucine labeling in dispersed rat pituitary cells\",\n      \"pmids\": [\"743954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery controlling granule maturation and sorting was not identified\", \"No direct comparison between constitutive and regulated secretory pathways\"]\n    },\n    {\n      \"year\": 1981,\n      \"claim\": \"Cloning and sequencing the human PRL cDNA and mapping the gene to chromosome 6 resolved the primary structure of pre-prolactin and established PRL as a single-locus gene distinct from GH/CS, providing the molecular foundation for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning from pituitary prolactinoma mRNA and somatic cell hybrid chromosomal mapping\",\n      \"pmids\": [\"6260780\", \"7221563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure of PRL itself was not yet determined\", \"Receptor identity and binding mode remained unknown\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Full genomic characterization revealed PRL as a single-copy ~10 kb gene with conserved intron–exon organization shared with GH, solidifying the gene duplication model and defining the transcriptional start site.\",\n      \"evidence\": \"Genomic library screening, restriction mapping, DNA sequencing, S1 nuclease mapping\",\n      \"pmids\": [\"6325171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulatory elements controlling pituitary-specific expression were not mapped\", \"Alternative promoter usage was unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Demonstrating that PRL and dopamine inhibit PRL release from the same lactotroph subpopulation via distinct intracellular mechanisms resolved a key question about whether autocrine PRL feedback and dopaminergic inhibition are parallel or convergent pathways.\",\n      \"evidence\": \"Reverse hemolytic plaque assay on single rat pituitary cells with chloroquine dissection\",\n      \"pmids\": [\"3093192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the PRL autocrine receptor pathway in lactotrophs was not defined\", \"Signaling intermediates downstream of each inhibitory mechanism were not characterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Discovery of an alternative upstream promoter ~6 kb 5' of the pituitary start site, producing the same mature PRL protein in decidua and lymphoblasts, explained how extrapituitary PRL expression is achieved independently of the pituitary transcription factor Pit-1.\",\n      \"evidence\": \"cDNA cloning, 5'-UTR sequencing, S1 mapping, and Northern blot from decidual and lymphoblast RNA\",\n      \"pmids\": [\"1697858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors driving the extrapituitary promoter were not yet identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showing that the extrapituitary PRL promoter is activated by cAMP independently of Pit-1 and progesterone receptor identified the signaling pathway controlling decidual/lymphoid PRL expression and distinguished it mechanistically from pituitary regulation.\",\n      \"evidence\": \"Promoter-reporter transfection in multiple cell types with Pit-1 co-expression and cAMP stimulation\",\n      \"pmids\": [\"8015553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cAMP-responsive transcription factors binding the extrapituitary promoter were not identified\", \"In vivo validation of cAMP requirement was lacking\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"The crystal structure of hGH bound to the hPRLR extracellular domain revealed the structural basis for sequential receptor engagement and cross-reactivity between GH and PRL receptor families, establishing the two-site binding paradigm.\",\n      \"evidence\": \"X-ray crystallography of hGH–hPRLR ECD complex\",\n      \"pmids\": [\"7984244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"A structure of PRL itself bound to PRLR was not yet available\", \"Transmembrane and intracellular conformational changes upon dimerization were unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mutagenesis of the Zn²⁺-binding site (H27A) demonstrated that Zn²⁺ promotes PRL self-association but is dispensable for receptor activation, separating storage/aggregation properties from signaling function.\",\n      \"evidence\": \"⁶⁵Zn binding, Scatchard analysis, Nb2 bioassay, CD spectroscopy, and sedimentation equilibrium on WT and H27A PRL\",\n      \"pmids\": [\"8833655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of Zn²⁺-dependent aggregation in pituitary granules was not tested in vivo\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Chimeric PRL receptor experiments demonstrated that different cytoplasmic domains (from IL-2Rβ or βc) all converge on STAT5 activation and β-casein transcription, establishing STAT5 as the obligate downstream effector regardless of the specific JAK kinase engaged.\",\n      \"evidence\": \"Stable CHO cells expressing chimeric PRLR with IL-2Rβ or βc cytoplasmic domains; phospho-JAK/STAT Western blot, EMSA, β-casein reporter\",\n      \"pmids\": [\"8721989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of STAT5a vs. STAT5b to specific target gene activation were not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Tissue-specific signaling outcomes of PRL were explained by showing that mammary gland (long-form PRLR dominant) activates JAK2/STAT5 in vivo while liver (short-form PRLR abundant) does not, implicating inactive heterodimers as a tissue-selective gating mechanism.\",\n      \"evidence\": \"In vivo PRL injection in ovario-hysterectomized rats with tissue-specific Co-IP, EMSA, and quantitative RT-PCR for receptor isoforms\",\n      \"pmids\": [\"9314595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration that short/long heterodimers are signaling-incompetent was not provided\", \"Mechanism preventing JAK2 activation in heterodimers was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"PRLR knockout mice established the non-redundant in vivo requirements for PRL signaling in female fertility, lactation, and pancreatic islet development, providing the definitive loss-of-function phenotypic framework.\",\n      \"evidence\": \"PRLR gene-targeted deletion in mice with reproductive, lactation, and islet phenotyping\",\n      \"pmids\": [\"9626554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of PRL vs. placental lactogen signaling through PRLR were not distinguished\", \"CNS-mediated behavioral phenotypes were incompletely characterized\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of a negative regulatory role for the PRLR C-terminal domain on MAPK activation—through recruitment of tyrosine and serine/threonine phosphatases—revealed an intrinsic feedback mechanism that limits mitogenic signaling.\",\n      \"evidence\": \"PRLR truncation/deletion mutants in CHO cells with pharmacological phosphatase inhibitors and phospho-ERK Western blot\",\n      \"pmids\": [\"10687859\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphatases recruited to the C-terminal domain were not identified\", \"In vivo significance of this feedback in mammary tissue was not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"PRL was shown to transcriptionally activate cyclin D1 through a STAT5a/5b heterodimer binding a distal GAS element in the cyclin D1 promoter, directly linking PRL–STAT5 signaling to cell cycle progression in mammary carcinoma cells.\",\n      \"evidence\": \"Cyclin D1 promoter-luciferase reporters, EMSA with STAT5-specific supershifts, STAT5a/5b co-IP from nuclear extracts, proliferation assays in mammary carcinoma cells\",\n      \"pmids\": [\"11923474\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT5 heterodimer vs. homodimer usage differs between normal and malignant mammary cells was not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Quantitative analysis of PRLR KO pancreata demonstrated that PRL/lactogenic signaling is required for normal islet density, beta-cell mass, and glucose-stimulated insulin secretion from early postnatal life, extending PRL's physiological roles beyond reproduction.\",\n      \"evidence\": \"PRLR knockout mouse morphometry, insulin mRNA quantification, static/dynamic insulin secretion assays, glucose tolerance testing\",\n      \"pmids\": [\"11897695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRL acts directly on beta cells or indirectly through islet vasculature/stroma was unresolved\", \"Compensatory mechanisms from other growth factors were not excluded\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that PRL directly inhibits lipoprotein lipase activity in human white adipose tissue via functional PRLR isoforms established a direct metabolic action on lipid partitioning.\",\n      \"evidence\": \"LPL enzyme activity assay in PRL-treated human adipose tissue explants with PRLR expression confirmed by RT-PCR and immunoblot\",\n      \"pmids\": [\"12679477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from PRLR to LPL inhibition was not delineated\", \"In vivo metabolic consequences in humans were not measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mass spectrometric identification of Ser-163 and Ser-194 phosphorylation on human pituitary PRL, with Ser-163 dephosphorylated in circulating PRL, defined post-translational modifications that distinguish stored and secreted hormone forms.\",\n      \"evidence\": \"Mass spectrometry, 2D electrophoresis, Western blot on pituitary and serum PRL\",\n      \"pmids\": [\"15687336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase(s) responsible for Ser-163/Ser-194 phosphorylation were not identified\", \"Functional consequences of each phosphorylation event on receptor binding or bioactivity were not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that human hair follicles express both PRL and PRLR and that exogenous PRL induces premature catagen established PRL as an autocrine/paracrine catagen-promoting factor in human skin.\",\n      \"evidence\": \"RT-PCR and immunohistology for PRL/PRLR in scalp follicles; organ culture with PRL and Ki-67/TUNEL morphometry\",\n      \"pmids\": [\"16507890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling pathway mediating catagen induction in follicular keratinocytes was not identified\", \"Relative contribution of locally produced vs. circulating PRL was unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that cathepsin D cleaves PRL into a 16 kDa antiangiogenic fragment in the context of cardiac STAT3 deficiency, and that this fragment is both necessary and sufficient for peripartum cardiomyopathy (PPCM), identified a pathogenic proteolytic product of PRL and established a causal mechanism for PPCM.\",\n      \"evidence\": \"Cardiomyocyte-specific Stat3 KO mice, cathepsin D activity assay, forced 16 kDa PRL expression, bromocriptine rescue, human PPCM patient serum analysis\",\n      \"pmids\": [\"17289576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial receptor for 16 kDa PRL was not identified\", \"Whether cathepsin D cleavage occurs intracellularly or extracellularly in the cardiac microenvironment was unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Elucidation of the 16 kDa PRL → miR-146a → exosome → cardiomyocyte axis provided the intercellular signaling mechanism by which the antiangiogenic PRL fragment damages the myocardium, identifying specific downstream targets (NRAS, Erbb4, Notch1, Irak1) in cardiomyocytes.\",\n      \"evidence\": \"miRNA profiling, NRAS 3'UTR luciferase reporter, exosome isolation/transfer, Stat3 KO mouse model, locked nucleic acid rescue, human PPCM plasma miR-146a measurement\",\n      \"pmids\": [\"23619365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which 16 kDa PRL induces miR-146a transcription in endothelial cells was not defined\", \"Therapeutic window for anti-miR-146a or bromocriptine intervention was not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A human stop-gain mutation (p.Arg220Ter) causing familial prolactin deficiency and alactogenesis demonstrated that the C-terminal disulfide bond is essential for PRL secretion, linking structural integrity to the secretory pathway and establishing a Mendelian form of PRL deficiency.\",\n      \"evidence\": \"Sanger sequencing, transfection of WT/mutant PRL, conditioned medium immunoassay and Nb2 bioassay for secretion\",\n      \"pmids\": [\"33770166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which C-terminal disulfide bond disruption blocks secretion (ER retention vs. degradation) was not resolved\", \"Prevalence of PRL mutations in idiopathic lactation failure is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the atomic structure of the PRL–PRLR ternary complex, the identity of kinases phosphorylating Ser-163/Ser-194, the endothelial receptor mediating 16 kDa PRL effects, and whether PRL acts directly on pancreatic beta cells or through islet accessory cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No PRL:PRLR ternary complex structure available\", \"Kinases for Ser-163/Ser-194 unidentified\", \"16 kDa PRL endothelial receptor unknown\", \"Direct vs. indirect beta-cell action unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [11, 19, 21, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [22, 24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 15, 30]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 14, 17, 19, 21, 27]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 23, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PRLR\",\n      \"JAK2\",\n      \"STAT5A\",\n      \"STAT5B\",\n      \"CTSD\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}